{"paper_id":"4e2cc9e0-0f0c-4e2b-93b5-aef75a81af3d","body_text":"[68Ga]-FAPI-04 outperforms [18F]-FDG in gastric cancer staging: a comparative study using PET/CT and PET/MR | Research Square window.SnipcartSettings = { analytics: { enabled: false } }; (function() { var accessVector = localStorage.getItem('access_vector') || ''; window.dataLayer = window.dataLayer || []; if (accessVector) { window.dataLayer.push({ user: { profile: { profileInfo: { snid: accessVector } } } }); } })(); (function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start':new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0],j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src='https://www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f);})(window,document,'script','dataLayer','GTM-K279D39R'); Browse Preprints In Review Journals COVID-19 Preprints AJE Video Bytes Research Tools Research Promotion AJE Professional Editing AJE Rubriq About Preprint Platform In Review Editorial Policies Our Team Advisory Board Help Center Sign In Submit a Preprint Cite Share Download PDF Research Article [68Ga]-FAPI-04 outperforms [18F]-FDG in gastric cancer staging: a comparative study using PET/CT and PET/MR Zhenghao Jiang, Lifang Pang, Yihan Yan, Masong Tang, Yiqiu Zhang This is a preprint; it has not been peer reviewed by a journal. https://doi.org/ 10.21203/rs.3.rs-8937576/v1 This work is licensed under a CC BY 4.0 License Status: Published Journal Publication published 20 Apr, 2026 Read the published version in Abdominal Radiology → Version 1 posted 9 You are reading this latest preprint version Abstract Purpose This study aimed to systematically compare the diagnostic performance of gallium-68–labeled fibroblast activation protein inhibitor-04 ([ 68 Ga]-FAPI-04) and fluorine-18 fluorodeoxyglucose ([ 18 F]-FDG) for gastric cancer staging using positron emission tomography combined with computed tomography (PET/CT) and positron emission tomography combined with magnetic resonance imaging (PET/MR). Methods In this single-center retrospective study, 35 patients with pathologically confirmed gastric cancer underwent sequential imaging with [ 68 Ga]-FAPI-04 (PET/CT and PET/MR) and [ 18 F]-FDG (PET/CT and/or PET/MR) within 48 hours. Diagnostic performance for primary tumors, lymph node metastases, and distant metastases was evaluated against histopathological results or clinical follow-up. Semi-quantitative parameters, including maximum standardized uptake value (SUV max ) and target-to-background ratio (TBR), were compared across tracers and modalities. Results [ 68 Ga]-FAPI-04 exhibited significantly higher SUV max and TBR than [ 18 F]-FDG in primary tumors, lymph node and peritoneal metastases. Notably, [ 68 Ga]-FAPI-04 maintained consistently high uptake in signet-ring cell carcinoma, a subtype where [ 18 F]-FDG uptake was significantly lower. [ 68 Ga]-FAPI-04 PET/MR achieved 100% sensitivity and specificity for peritoneal metastases, significantly outperforming all [ 18 F]-FDG-based modalities. While whole-body PET/CT yielded higher absolute SUV max values, PET/MR demonstrated superior performance in terms of TBR. Conclusion [ 68 Ga]-FAPI-04 outperforms [ 18 F]-FDG in visualizing primary and metastatic gastric cancer lesions. The combination of [ 68 Ga]-FAPI-04 and PET/MR is a particularly effective imaging strategy, delivering superior diagnostic performance for detecting peritoneal metastases and evaluating [ 18 F]-FDG-insensitive subtypes, thereby optimizing precise staging. Gastric cancer [68Ga]-FAPI-04 [18F]-FDG PET/CT PET/MR Figures Figure 1 Figure 2 Figure 3 Figure 4 Key Points Question Accurate staging of gastric cancer, especially for FDG-insensitive subtypes and peritoneal metastases, remains clinically challenging. Findings [ 68 Ga]-FAPI-04 PET/CT and PET/MR outperforms [ 18 F]-FDG in detecting primary tumors, lymph node, and peritoneal metastases of gastric cancer. Clinical Relevance [ 68 Ga]-FAPI-04 combined with PET/MR optimizes gastric cancer staging, aiding personalized treatment decisions for FDG-insensitive subtypes and peritoneal metastases. Introduction Gastric cancer is the fifth most common malignancy and a leading cause of cancer-related death worldwide [1]. Accurate staging is critical for personalized treatment as it directly impacts prognosis [2] , but precise preoperative staging remains a clinical challenge. Current staging relies on multimodal imaging. Endoscopy is the diagnostic cornerstone, while CT is the primary modality for distant metastasis evaluation [2]. However, CT has limitations in local T-stage assessment, lymph node detection, and peritoneal metastasis identification [3]. [ 18 F]-fluorodeoxyglucose ([ 18 F]-FDG) PET/CT is recommended for occult metastasis detection before curative treatment [4]. Nevertheless, it has intrinsic drawbacks: low metabolic activity causes false negatives in subtypes like signet-ring cell carcinoma (SRCC) [5], and physiological abdominal uptake compromises peritoneal metastasis accuracy [6]. Gallium-68–labeled fibroblast activation protein inhibitor-04 ([ 68 Ga]-FAPI-04) is a novel stroma-targeted radiotracer binding to fibroblast activation protein (FAP) [7], a promising imaging target. Preliminary evidence shows it outperforms [ 18 F]-FDG PET/CT in detecting gastric cancer lesions [8] , but most studies are limited to PET/CT alone. In contrast, MR provides superior soft-tissue contrast, benefiting local T-staging and peritoneal assessment [9]. To date, systematic comparisons of both radiotracers across PET/CT and PET/MR for gastric cancer staging are scarce. Thus, this study aims to comprehensively compare the diagnostic performance of [ 68 Ga]-FAPI-04 and [ 18 F]-FDG in detecting primary and metastatic gastric cancer lesions using both modalities. Materials and methods Patient enrollment This single-center retrospective study was conducted at Zhongshan Hospital, Fudan University. The study protocol was approved by the Institutional Review Board (IRB; No. B2022-098R2), and written informed consent was obtained from each patient. Between May 2022 and May 2025, patients who underwent sequential PET imaging with [ 68 Ga]-FAPI-04 and [ 18 F]-FDG within a 48-hour window were retrospectively enrolled. For [ 68 Ga]-FAPI-04 imaging, both PET/CT and PET/MR data were acquired concurrently. In contrast, [ 18 F]-FDG imaging comprised PET/CT, PET/MR, or both modalities. The inclusion criteria were as follows: (a) histological diagnosis of gastric cancer; (b) completion of paired [ 18 F]-FDG and [ 68 Ga]-FAPI-04 PET/CT and PET/MR for tumor staging to determine the optimal treatment strategy; and (c) provision of written informed consent. The exclusion criteria were: (a) prior anti-tumor therapy; (b) presence of concomitant malignant neoplasms; and (c) insufficient clinical or follow-up data. Preparation of [ 18 F]-FDG and [ 68 Ga]-FAPI-04 [ 18 F]-FDG was synthesized following the standard institutional protocol using an [ 18 F]-FDG synthesis module (PET-FDG-IT-NA; PET Technology Co., Ltd., Beijing, China). The FAPI precursor, 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA)-conjugated FAPI-04, was obtained from Huayi Technology Co., Ltd. (Jiangsu, China). Radiolabeling of DOTA-FAPI-04 was performed by combining 100 μg of the precursor with 1 mL of 0.25 M sodium acetate and 4 mL of 68 Ga solution (370 MBq in 0.05 M HCl). The reaction mixture was incubated at 95°C for 10 minutes, yielding a final pH of approximately 6.0. Radio-high-performance liquid chromatography (R-HPLC) analysis confirmed that the radiochemical yields of both [ 18 F]-FDG and [ 68 Ga]-DOTA-FAPI-04 exceeded 90%. Finally, both tracers were diluted with saline and sterilized by passage through a 0.22-μm filter (Millipore, Billerica, MA, USA) into a sterile syringe. R-HPLC verified that the radiochemical purity of both tracers was greater than 98%. PET/MR and PET/CT scan protocols Patients underwent PET imaging with [ 68 Ga]-FAPI-04 and [ 18 F]-FDG within a 48-hour window. Following intravenous administration of [ 68 Ga]-FAPI-04 (1.85–3.70 MBq/kg), whole-body PET/MR (uPMR 790 HD TOF PET/MR system; United Imaging Healthcare, Shanghai, China) and PET/CT (uEXPLORER; United Imaging Healthcare) were performed sequentially approximately 30–60 minutes post-injection, with a median interval of 82 minutes (range: 49–143 minutes) between scans. Patients fasted for at least 6 hours prior to the administration of [ 18 F]-FDG (3.7 MBq/kg), and blood glucose levels were maintained below 11.0 mmol/L. Approximately 60 minutes after [ 18 F]-FDG injection, PET/CT, PET/MR, or both were performed. If both scans were conducted, PET/MR was performed first, followed by PET/CT, with a median interval of 71 minutes (range: 49–106 minutes). A low-dose CT scan (5–10 mAs, 120 kV) was acquired first for attenuation correction (AC), followed by a diagnostic free-breathing CT scan using modulated tube current and voltage (120 kV for the body; 258 mAs and 120 kV for the head). Static PET images were acquired over 10 minutes and reconstructed using the ordered subset expectation maximization algorithm (slice thickness, 1.443 mm; 3 iterations; 20 subsets; matrix, 192 × 192). PET/MR imaging included a whole-body scan and a dedicated abdominal scan. Patients were positioned using dedicated whole-body and head coils. Earplugs were provided to minimize gradient noise, and foam wedges were used to stabilize the head. For magnetic resonance attenuation correction (MRAC), a 3D T1-weighted spoiled gradient-echo sequence combined with Dixon-based water-fat separation imaging (WFI) was acquired in the coronal plane (repetition time [TR] = 4.6 ms; echo time [TE] = 3.2 ms; slice thickness = 2.4 mm; field of view [FOV] = 500 × 350 mm; matrix = 206 × 144; acquisition time = 31 seconds). Compressed sensing technology was employed to accelerate data acquisition. Tissue segmentation and attenuation coefficient map (μ-map) calculation were automatically performed via the vendor-supplied algorithm. Whole-body PET data were acquired in 3D list mode with five bed positions (average acquisition time: 3 minutes per bed; overlap: 30%) covering the region from the skull base to the proximal thighs. Image analysis All [ 18 F]-FDG and [ 68 Ga]-FAPI-04 PET/CT and PET/MR images were independently reviewed and interpreted by two experienced nuclear medicine physicians using a dedicated United Imaging workstation (United Imaging Healthcare, Shanghai, China), with final interpretations reached by consensus. A primary or metastatic lesion was considered positive when focal tracer uptake exceeded background activity and corresponded to abnormal findings on CT or MR images, after exclusion of potential confounders such as physiological uptake, trauma, infection, or inflammation. For peritoneal metastases, CT and MR images were jointly evaluated to differentiate diffuse pathological involvement from physiological intestinal uptake and to distinguish nodular peritoneal lesions from hypermetabolic lymph nodes. For suspected bone metastases, CT and MR findings were used to exclude benign conditions, including Schmorl’s nodes, hyperostosis, and degenerative changes. Semi-quantitative analysis was performed by manually delineating regions of interest (ROIs) along the lesion margins on axial images. The maximum standardized uptake value (SUV max ) was automatically calculated by the system. The target-to-background ratio (TBR) was defined as the ratio of lesion SUV max to the mean standardized uptake value of normal liver tissue. PET/CT and PET/MR findings were validated against histopathological results obtained from gastroscopy or surgical specimens. When histopathological confirmation was unavailable, clinical follow-up data, including laboratory results and serial imaging findings over a minimum period of three months, were used as a reference standard. Tumors were staged according to the 8th Edition of the American Joint Committee on Cancer (AJCC) Cancer Staging Manual. Statistical analysis Statistical analyses were performed using SPSS software (version 27.0.1; IBM Corp., Armonk, NY, USA). Continuous variables were summarized as mean ± standard deviation (SD), and categorical variables were presented as counts and percentages. The Wilcoxon signed-rank test was applied to evaluate differences in SUV max and TBR between groups, and McNemar's test was used to compare diagnostic performance. A two-tailed P -value < 0.05 was considered statistically significant. Results Patient characteristics The study design is illustrated in Fig. 1. A total of 35 patients with pathologically confirmed gastric cancer, diagnosed by surgical resection or gastroscopic biopsy, were included in the analysis. All patients underwent [ 68 Ga]-FAPI PET/CT and PET/MR. Among them, 21 patients underwent both [ 18 F]-FDG PET/CT and PET/MR, 13 underwent only [ 18 F]-FDG PET/MR, and 1 underwent only [ 18 F]-FDG PET/CT. According to imaging-based staging, 18 patients with early-stage disease proceeded to surgical resection, whereas the remaining 17 patients received systemic treatment, including chemotherapy, immunotherapy, or targeted therapy. Detailed patient characteristics are summarized in Table 1. Comparison of [ 68 Ga]-FAPI-04 and [ 18 F]-FDG in the detection of primary tumors A total of 35 patients with 35 evaluable primary lesions were included in the primary lesion analysis. The mean depth of primary gastric cancer lesions was 16.1 ± 5.6 mm (range, 4.1–33.8 mm). The diagnostic performance of [ 68 Ga]-FAPI-04 and [ 18 F]-FDG using PET/CT and PET/MR is summarized in Table 2. In patient-based analyses, [ 68 Ga]-FAPI-04 PET/CT and PET/MR each achieved a primary tumor detection rate of 97.1% (34/35). For [ 18 F]-FDG, detection rates were 95.5% (21/22) with PET/CT and 97.1% (33/34) with PET/MR, with no statistically significant differences observed among the four modalities (all p= 1.000). The single lesion missed by all modalities was pathologically confirmed as SRCC confined to the lamina propria and was also negative on both CT and MR. When comparing tracers on the same imaging platform, [ 68 Ga]-FAPI-04 demonstrated significantly higher tracer uptake than [ 18 F]-FDG on both PET/CT (SUV max : 11.18 ± 5.32 vs. 3.79 ± 2.03, p ＜0.001) and PET/MR (SUV max : 9.39 ± 4.42 vs. 3.37 ± 2.23, p ＜0.001). Correspondingly, TBR values were significantly higher for [ 68 Ga]-FAPI-04 than for [ 18 F]-FDG on PET/CT (13.81 ± 10.00 vs. 2.04 ± 1.02, p ＜ 0.001) and PET/MR (16.35 ± 13.34 vs. 2.18 ± 1.28, p ＜0.001). When comparing the same tracer across imaging platforms, [ 18 F]-FDG PET/CT yielded slightly higher SUV max than PET/MR (3.79 ± 2.03 vs. 3.37 ± 2.23, p= 0.010), with no significant difference in TBR ( p= 0.476). Similarly, [ 68 Ga]-FAPI-04 PET/CT showed higher SUV max than PET/MR (11.18 ± 5.32 vs. 9.39 ± 4.42, p ＜0.001), whereas PET/MR demonstrated a significantly higher TBR than PET/CT (16.35 ± 13.34 vs. 13.81 ± 10.00, p= 0.020) (Fig. 2). Pathological analysis identified SRCC in 20 of 35 patients. In the SRCC subgroup, both SUV max and TBR of [ 68 Ga]-FAPI-04 were significantly higher than those of [ 18 F]-FDG on PET/CT (SUV max : 10.20 ± 5.62 vs. 3.06 ± 2.82, p= 0.001; TBR: 11.33 ± 7.90 vs. 1.71 ± 0.83, p ＜0.001) and PET/MR (SUV max : 8.37 ± 4.11 vs. 2.66 ± 1.37, p ＜0.001; TBR: 12.91 ± 9.93 vs. 1.73 ± 0.92, p ＜0.001). Similar findings were observed in the non-SRCC subgroup, in which [ 68 Ga]-FAPI-04 also demonstrated significantly higher SUV max and TBR than [ 18 F]-FDG across both modalities (all p ＜0.05). Significant differences in [ 18 F]-FDG uptake were observed between the non-SRCC and SRCC groups, including PET/CT SUV max (U = 26.0, p= 0.040), PET/MR SUV max (U = 68 .0, p= 0.012), and corresponding TBR values ( p= 0.041 and p= 0.005, respectively). In contrast, no significant differences were detected between the two histological subgroups for any [ 68 Ga]-FAPI-04 uptake parameters on either imaging platform (all p > 0.05). Comparison of [ 68 Ga]-FAPI-04 and [ 18 F]-FDG in the detection of lymph nodal metastases Among the 35 patients included in the analysis, 21 were confirmed to have regional lymph node metastases based on histopathological findings or clinical follow-up. The diagnostic performance of the different imaging modalities is summarized in Table 2. In patient-based comparisons, only [ 68 Ga]-FAPI-04 PET/MR demonstrated a statistically significant advantage over [ 18 F]-FDG PET/MR (χ 2 = 7.11, p= 0.008). No significant differences were observed in the remaining pairwise comparisons between imaging modalities (all p >0.05). Lesion-based analysis of lymph node metastases was not fully feasible, as histopathological confirmation was unavailable for all evaluated lymph nodes, precluding comprehensive assessment of diagnostic efficacy at the lesion level. As illustrated in Fig. 3, a 26-year-old female with poorly differentiated gastric cancer (endoscopic biopsy-proven) showed intense tracer uptake in regional lymph nodes (red arrows) on [ 68 Ga]-FAPI-04 PET/CT and PET/MR, while [ 18 F]-FDG PET/MR showed negative nodal findings. Lymph node enlargement relative to the baseline on 6-month follow-up CT imaging corroborated the lymph node-positive findings of [ 68 Ga]-FAPI-04 imaging. Analysis of patients who received lymphadenectomy Among the 18 patients who underwent lymphadenectomy, 14 completed all four imaging examinations. A total of 530 lymph nodes were dissected, of which 94 metastatic nodes were identified in 9 patients. N-staging results based on [ 18 F]-FDG and [ 68 Ga]-FAPI-04 PET/CT and PET/MR are summarized in Table 3. In patient-based analyses, [ 18 F]-FDG PET/CT correctly classified 8 cases; two cases with increased FDG uptake were pathologically confirmed as false positives, and the remaining misclassified cases were attributable to false-negative findings. [ 18 F]-FDG PET/MR correctly classified 9 cases and misclassified 5 cases. In contrast, both [ 68 Ga]-FAPI-04 PET/CT and PET/MR correctly classified 12 cases and misclassified 2 cases. Using histopathology as the reference standard, [ 68 Ga]-FAPI-04 PET/CT and PET/MR accurately predicted N stage in 50.0% (7/14) of patients, with underestimation in the remaining 50.0% (7/14). By comparison, [ 18 F]-FDG PET/CT accurately staged 28.6% (4/14) of patients, underestimated N stage in 57.1% (8/14), and overestimated it in 14.3% (2/14). N-staging performance of [ 18 F]-FDG PET/MR was comparable to that of [ 18 F]-FDG PET/CT, with no statistically significant difference ( p >0.05). Lesion-based analysis of the 530 resected lymph nodes showed that [ 18 F]-FDG PET/CT identified 19 true positives, 5 false positives, 431 true negatives, and 75 false negatives, whereas [ 18 F]-FDG PET/MR identified 21 true positives, 3 false positives, 433 true negatives, and 73 false negatives. In contrast, [ 68 Ga]-FAPI-04 PET/CT and PET/MR demonstrated identical performance, jointly identifying 25 true positives, no false positives, 436 true negatives, and 69 false negatives. Accordingly, [ 68 Ga]-FAPI-04 PET/CT and PET/MR achieved higher sensitivity, specificity, accuracy, PPV, and NPV than [ 18 F]-FDG PET/CT and PET/MR. A statistically significant difference was observed when comparing [ 68 Ga]-FAPI-04 PET/CT or PET/MR with [ 18 F]-FDG PET/CT (χ 2 = 4.17, p= 0.041), whereas no significant difference was detected compared with [ 18 F]-FDG PET/MR (χ 2 = 2.08, p= 0.149). In semi-quantitative analyses, [ 68 Ga]-FAPI-04 PET/CT demonstrated significantly higher SUV max (6.71 ± 5.26 vs. 2.81 ± 2.50, p ＜0.001) and TBR (9.33 ± 7.90 vs. 1.61 ± 1.45, p ＜0.001) than [ 18 F]-FDG PET/CT. Similar findings were observed for PET/MR, with [ 68 Ga]-FAPI-04 showing higher SUV max (5.71 ± 3.93 vs. 3.46 ± 4.47, p ＜0.001) and TBR (11.40 ± 10.98 vs. 2.03 ± 2.31, p ＜0.001) than [ 18 F]-FDG PET/MR. For the same radiotracer, no significant differences in SUV max or TBR were observed between [ 18 F]-FDG PET/CT and PET/MR (all p ＞0.05). In contrast, [ 68 Ga]-FAPI-04 PET/CT yielded higher SUV max than PET/MR (6.71 ± 5.26 vs. 5.71 ± 3.93, p ＜0.001), whereas PET/MR demonstrated a significantly higher TBR than PET/CT (11.40 ± 10.98 vs. 9.33 ± 7.90, p ＜0.001) (Fig. 2). Comparison of [ 68 Ga ] -FAPI-04 and [ 18 F]-FDG in the detection of peritoneal metastasis Among the 35 patients included in the analysis, 21 were confirmed to have peritoneal metastases based on histopathology or clinical follow-up. Of these, 9 cases were verified by laparoscopic exploration, while the remaining cases were confirmed through follow-up of more than three months, incorporating imaging and serological evidence. The diagnostic performance of the different imaging modalities is summarized in Table 2. In patient-based comparisons between radiopharmaceuticals, [ 68 Ga]-FAPI-04 PET/CT demonstrated significantly superior performance compared with both [ 18 F]-FDG PET/CT (χ 2 = 4.17, p= 0.041) and [ 18 F]-FDG PET/MR (χ 2 = 5.14, p= 0.023). Similarly, [ 68 Ga]-FAPI-04 PET/MR showed statistically significant advantages over [ 18 F]-FDG PET/CT (χ 2 = 5.14, p= 0.023) and [ 18 F]-FDG PET/MR (χ 2 = 6.13, p= 0.013). No significant differences were observed between PET/CT and PET/MR when using the same radiopharmaceutical, either for [ 18 F]-FDG (χ 2 = 2.00, p= 0.157) or for [ 68 Ga]-FAPI-04 (χ 2 = 0, p= 1.000). In lesion-based analysis, a total of 47 pathologically or follow-up–confirmed peritoneal lesions were identified in the 21 patients. Sensitivity was 42.9% (12/28) for [ 18 F]-FDG PET/CT, 66.0% (31/47) for [ 18 F]-FDG PET/MR, 91.5% (43/47) for [ 68 Ga]-FAPI-04 PET/CT, and 100.0% (47/47) for [ 68 Ga]-FAPI-04 PET/MR. Cross-radiopharmaceutical comparisons showed that both [ 68 Ga]-FAPI-04 PET/CT and PET/MR significantly outperformed [ 18 F]-FDG PET/CT and PET/MR ( all p ≤ 0.001). No significant difference was observed between PET/CT and PET/MR for [ 68 Ga]-FAPI-04 (χ 2 = 0.25, p= 0.617). In contrast, [ 18 F]-FDG PET/MR demonstrated significantly higher sensitivity than [ 18 F]-FDG PET/CT (χ 2 = 4.57, p= 0.033). As shown in Fig. 4, a 33-year-old female with signet ring cell gastric cancer (endoscopic biopsy-proven) exhibited prominent tracer accumulation in peritoneal lesions (white arrows) on [ 68 Ga]-FAPI-04 PET/CT and PET/MR, while [ 18 F]-FDG PET/CT and PET/MR showed no such findings. Ultrasound-guided needle biopsy of these peritoneal lesions confirmed metastatic poorly differentiated carcinoma. When comparing radiopharmaceuticals on the same imaging platform, [ 68 Ga]-FAPI-04 PET/CT showed significantly higher SUV max than [ 18 F]-FDG PET/CT (7.08 ± 3.61 vs. 2.71 ± 2.83, p ＜0.001), and [ 68 Ga]-FAPI-04 PET/MR likewise demonstrated higher SUV max than [ 18 F]-FDG PET/MR (5.88 ± 3.27 vs. 1.94 ± 1.57, p ＜0.001). Correspondingly, TBR values were significantly higher for [ 68 Ga]-FAPI-04 than for [ 18 F]-FDG on both PET/CT (8.25 ± 5.27 vs. 1.50 ± 1.55, p ＜0.001) and PET/MR (9.31 ± 6.28 vs. 1.28 ± 0.91, p ＜0.001). When comparing the same radiopharmaceutical across imaging platforms, [ 68 Ga]-FAPI-04 PET/CT demonstrated a higher SUV max than PET/MR (7.08 ± 3.61 vs. 5.88 ± 3.27, p ＜0.001), whereas PET/MR yielded a significantly higher TBR than PET/CT (9.31 ± 6.28 vs. 8.25 ± 5.27, p= 0.025). For [ 18 F]-FDG, no significant differences in SUV max or TBR were observed between PET/CT and PET/MR ( p= 0.353 and p= 0.086, respectively) (Fig. 2). Comparison of [ 68 Ga]-FAPI-04 and [ 18 F]-FDG in the detection of other metastases The diagnostic performance of the four imaging modalities for the detection of ovarian and bone metastases is summarized in Table 2. Patient-based analysis was not performed because of the limited number of positive cases. In lesion-based analyses, no statistically significant differences were observed among the four imaging modalities in the detection of either ovarian or bone metastases (all p >0.05). In semi-quantitative analyses comparing radiopharmaceuticals on the same imaging platform, ovarian metastases demonstrated significantly higher SUV max and TBR with [ 68 Ga]-FAPI-04 than with [ 18 F]-FDG on both PET/CT (SUV max : 4.41 ± 1.87 vs. 2.45 ± 0.75, p= 0.043; TBR: 5.05 ± 2.85 vs. 1.36 ± 0.46, p= 0.043) and PET/MR (SUV max : 3.03 ± 0.87 vs. 1.94 ± 0.91, p= 0.008; TBR: 6.58 ± 7.01 vs. 1.18 ± 0.20, p= 0.008). In contrast, for bone metastases, only the TBR measured with [ 68 Ga]-FAPI-04 PET/MR was significantly higher than that measured with [ 18 F]-FDG PET/MR (13.50 ± 14.37 vs. 2.91 ± 1.37, p= 0.038). When comparing the same radiopharmaceutical across different imaging platforms, [ 68 Ga]-FAPI-04 PET/CT demonstrated a significantly higher SUV max than PET/MR for ovarian metastases (21.81 vs. 15.12, p= 0.015), whereas no significant difference in TBR was observed ( p= 0.515). For [ 18 F]-FDG, no significant inter-platform differences were detected, likely reflecting the limited sample size. Similarly, statistical comparisons for bone metastases remained inconclusive because of the small number of cases (Fig. 2). Discussion This study represents the first systematic, head-to-head comparison of the diagnostic performance of [ 68 Ga]-FAPI-04 versus [ 18 F]-FDG for gastric cancer staging across dual-modality PET/CT and PET/MR platforms. Our findings demonstrate that [ 68 Ga]-FAPI-04, a tumor-stroma-targeting tracer, outperforms [ 18 F]-FDG in detecting primary gastric cancer lesions and metastases. Crucially, this study underscores the substantial influence of the imaging modality itself on diagnostic performance, highlighting the unique value of PET/MR for assessing peritoneal metastases and delivering superior lesion contrast. The superior performance of [ 68 Ga]-FAPI-04 originates from its distinct mechanism of action. By targeting CAFs, which are characterized by high FAP expression within the tumor microenvironment, this tracer facilitates high-contrast visualization of gastric cancer lesions [10; 11]. We confirmed that, irrespective of the imaging platform (PET/CT or PET/MR), the SUV max and TBR of [ 68 Ga]-FAPI-04 in primary tumors, lymph nodes, and peritoneal metastases were significantly higher than those of [ 18 F]-FDG. The false-negative lesions undetected by both tracers were pathologically confirmed as SRCC confined to the lamina propria; these were also missed by CT and MR, likely due to their minute size. Previous studies have reported lower [ 18 F]-FDG uptake in SRCC and mucinous adenocarcinoma compared to conventional adenocarcinoma, a phenomenon associated with reduced expression of glucose transporter 1 (GLUT-1) [12]. Our subgroup analysis revealed significantly higher [ 68 Ga]-FAPI-04 uptake than [ 18 F]-FDG in 15 patients with SRCC, a finding consistent with prior research [13; 14]. However, in the non-SRCC group, [ 68 Ga]-FAPI-04 uptake (SUV max and TBR) was also significantly higher than that of [ 18 F]-FDG. This result differs from the findings reported by Rong et al. [8]. This discrepancy may be attributed to the fact that CAFs are a major component of the tumor stroma in most epithelial-derived tumors, including all histological subtypes of gastric cancer, and typically exhibit high FAP expression [15]. Non-SRCC tumors showed higher [ 18 F]-FDG uptake (including SUV max and TBR) than SRCC (all p ＜0.05), reflecting higher tumor cell metabolic activity. This confirms the well-recognized clinical challenge that SRCC, as a hypometabolic subtype, often leads to insufficient sensitivity on FDG PET [16]. In contrast, [ 68 Ga]-FAPI-04 showed no significant difference in uptake between the two subgroups (all p >0.05). This advantage is particularly critical for detecting peritoneal metastases, with [ 68 Ga]-FAPI-04 PET/MR achieving 100% sensitivity and specificity. We found that [ 68 Ga]-FAPI-04 outperformed [ 18 F]-FDG in detecting peritoneal metastases providing more distinct tracer uptake (Fig.4), which aligns with previous reports [9; 17-19]. This effectively overcomes the limitations of [ 18 F]-FDG associated with tumor metabolic heterogeneity and physiological abdominal uptake [20-22]. Lymph node staging is crucial for gastric cancer management and prognosis, yet the value of [ 18 F]-FDG PET/CT in this context remains controversial. Our study, which used postoperative pathology as the gold standard in 14 surgically treated patients, found higher [ 68 Ga]-FAPI-04 uptake in metastatic lymph nodes compared to [ 18 F]-FDG (Fig.3), consistent with previous studies [8; 20]. However, the diagnostic sensitivities across the four imaging modalities were relatively low (approximately 20–27%), consistent with prior reports [9]. The primary reason is that most dissected lymph nodes were small in volume, making them difficult to detect even with the high soft-tissue resolution of MR [23; 24]. Regarding imaging modalities, PET/CT and PET/MR exhibited distinct utilities and a complementary relationship. A key finding was that for the same tracer, SUV max measured by the uEXPLORER total-body PET/CT was consistently higher than that obtained from PET/MR. This primarily arises from inherent differences in attenuation correction principles and reconstruction algorithms, combined with the uEXPLORER scanner's ultra-high system sensitivity and extended axial field of view, which enable extremely low noise and precise quantitative analysis [25-27]. However, for lesion detection and contrast, PET/MR leveraged its superior soft-tissue resolution and different attenuation correction approaches to yield a superior TBR in most instances [9; 28; 29]. This advantage synergized with the highly specific FAP tracer, rendering PET/MR more adept at identifying subtle peritoneal implants, miliary nodules, and accurately assessing the local invasion extent of primary tumors [30]. The innovations of this study include the first systematic assessment of [ 68 Ga]-FAPI-04 versus [ 18 F]-FDG for gastric cancer staging across dual PET/CT and PET/MR platforms, and the pioneering application of the state-of-the-art uEXPLORER PET/CT system, whose ultra-high sensitivity and total-body coverage offered unique advantages for precise quantitative analysis. Several limitations must be acknowledged. First, this was a single-center, retrospective study with a relatively small sample size in specific metastatic subgroups. Second, the high proportion of SRCC in our cohort (57.1%), while underscoring the diagnostic advantage of [ 68 Ga]-FAPI-04 for hypometabolic tumors, may limit the generalizability of findings to populations with different pathological distributions. Third, most patients lacked surgical or histopathological confirmation of metastases, with validation primarily based on clinical follow-up and other imaging modalities. Finally, the sample sizes for bone and ovarian metastases were limited; these results are therefore exploratory, and statistically robust comparisons necessitate validation in larger cohorts. Future prospective, multi-center studies are warranted to validate these findings. Conclusion The combination of the tumor-stroma-targeting tracer [ 68 Ga]-FAPI-04 and PET/MR represents one of the most promising imaging strategies for gastric cancer staging, effectively leveraging the superior soft-tissue resolution of MRI. This approach is particularly valuable for detecting peritoneal metastases and evaluating [ 18 F]-FDG-insensitive tumor subtypes. The demonstrated advantages of [ 68 Ga]-FAPI-04 over [ 18 F]-FDG, coupled with the added diagnostic value of PET/MR relative to PET/CT in key clinical scenarios, provide compelling evidence for the utility of this strategy in refining gastric cancer staging and optimizing personalized treatment decisions. References Bray F, Laversanne M, Sung H et al (2024) Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 74:229-263 Sundar R, Nakayama I, Markar SR et al (2025) Gastric cancer. Lancet 405:2087-2102 Giandola T, Maino C, Marrapodi G et al (2023) Imaging in Gastric Cancer: Current Practice and Future Perspectives. Diagnostics (Basel) 13 Ajani JA, D'Amico TA, Bentrem DJ et al (2022) Gastric Cancer, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw 20:167-192 Filik M, Kir KM, Aksel B et al (2015) The Role of 18F-FDG PET/CT in the Primary Staging of Gastric Cancer. Mol Imaging Radionucl Ther 24:15-20 Song Z, Wu Y, Yang J, Yang D, Fang X (2017) Progress in the treatment of advanced gastric cancer. Tumour Biol 39:1010428317714626 Wang Y, Luo W, Li Y (2023) [(68)Ga]Ga-FAPI-04 PET MRI/CT in the evaluation of gastric carcinomas compared with [(18)F]-FDG PET MRI/CT: a meta-analysis. Eur J Med Res 28:34 Lin R, Lin Z, Chen Z et al (2022) [(68)Ga]Ga-DOTA-FAPI-04 PET/CT in the evaluation of gastric cancer: comparison with [(18)F]FDG PET/CT. Eur J Nucl Med Mol Imaging 49:2960-2971 Qin C, Shao F, Gai Y et al (2022) (68)Ga-DOTA-FAPI-04 PET/MR in the Evaluation of Gastric Carcinomas: Comparison with (18)F-FDG PET/CT. J Nucl Med 63:81-88 Fu Y, Qin C, Li M et al (2025) Comparative Evaluation of 68Ga-FAPI-04 PET for Initial N and M Staging in Gastric Cancer: A Study Against Histopathology and Contrast-Enhanced CT. Clin Nucl Med 50:394-403 Jiang D, Chen X, You Z et al (2022) Comparison of [(68) Ga]Ga-FAPI-04 and [(18)F]-FDG for the detection of primary and metastatic lesions in patients with gastric cancer: a bicentric retrospective study. Eur J Nucl Med Mol Imaging 49:732-742 Koppula BR, Fine GC, Salem AE et al (2022) PET-CT in Clinical Adult Oncology: III. Gastrointestinal Malignancies. Cancers (Basel) 14 Wang T, Huang G, Zhao H et al (2024) [(68)Ga]Ga-FAPI-04 PET/MR imaging strategy in management of Krukenberg tumors (KTs) from gastric signet-ring-cell carcinoma: to overcome limitation of [(68)Ga]Ga-FAPI-04 PET imaging in KTs. Eur J Nucl Med Mol Imaging 51:3440-3449 Chen H, Pang Y, Li J et al (2023) Comparison of [(68)Ga]Ga-FAPI and [(18)F]FDG uptake in patients with gastric signet-ring-cell carcinoma: a multicenter retrospective study. Eur Radiol 33:1329-1341 Oya Y, Hayakawa Y, Koike K (2020) Tumor microenvironment in gastric cancers. Cancer Sci 111:2696-2707 Stahl A, Ott K, Weber WA et al (2003) FDG PET imaging of locally advanced gastric carcinomas: correlation with endoscopic and histopathological findings. Eur J Nucl Med Mol Imaging 30:288-295 Zhao L, Pang Y, Luo Z et al (2021) Role of [(68)Ga]Ga-DOTA-FAPI-04 PET/CT in the evaluation of peritoneal carcinomatosis and comparison with [(18)F]-FDG PET/CT. Eur J Nucl Med Mol Imaging 48:1944-1955 Kuten J, Levine C, Shamni O et al (2022) Head-to-head comparison of [(68)Ga]Ga-FAPI-04 and [(18)F]-FDG PET/CT in evaluating the extent of disease in gastric adenocarcinoma. Eur J Nucl Med Mol Imaging 49:743-750 Li C, Tian Y, Chen J et al (2023) Usefulness of [(68)Ga]FAPI-04 and [(18)F]FDG PET/CT for the detection of primary tumour and metastatic lesions in gastrointestinal carcinoma: a comparative study. Eur Radiol 33:2779-2791 Pang Y, Zhao L, Luo Z et al (2021) Comparison of (68)Ga-FAPI and (18)F-FDG Uptake in Gastric, Duodenal, and Colorectal Cancers. Radiology 298:393-402 Yang T, Ma L, Hou H, Gao F, Tao W (2021) FAPI PET/CT in the Diagnosis of Abdominal and Pelvic Tumors. Front Oncol 11:797960 Qin C, Song Y, Gai Y et al (2022) Gallium-68-labeled fibroblast activation protein inhibitor PET in gastrointestinal cancer: insights into diagnosis and management. Eur J Nucl Med Mol Imaging 49:4228-4240 Liu B, Ramalho M, AlObaidy M et al (2014) Gastrointestinal imaging-practical magnetic resonance imaging approach. World J Radiol 6:544-566 Kwee RM, Kwee TC (2009) Imaging in assessing lymph node status in gastric cancer. Gastric Cancer 12:6-22 Zhang X, Xie Z, Berg E et al (2020) Total-Body Dynamic Reconstruction and Parametric Imaging on the uEXPLORER. J Nucl Med 61:285-291 Wu Y, Feng T, Zhao Y et al (2022) Whole-Body Parametric Imaging of (18)F-FDG PET Using uEXPLORER with Reduced Scanning Time. J Nucl Med 63:622-628 Liu G, Mao W, Yu H, Hu Y, Gu J, Shi H (2023) One-stop [(18)F]FDG and [(68)Ga]Ga-DOTA-FAPI-04 total-body PET/CT examination with dual-low activity: a feasibility study. Eur J Nucl Med Mol Imaging 50:2271-2281 Drzezga A, Souvatzoglou M, Eiber M et al (2012) First clinical experience with integrated whole-body PET/MR: comparison to PET/CT in patients with oncologic diagnoses. J Nucl Med 53:845-855 Fürst S, Grimm R, Hong I et al (2015) Motion correction strategies for integrated PET/MR. J Nucl Med 56:261-269 Zheng W, Liu L, Feng Y, Wang L, Chen Y (2023) Comparison of 68 Ga-FAPI-04 and fluorine-18-fluorodeoxyglucose PET/computed tomography in the detection of ovarian malignancies. Nucl Med Commun 44:194-203 Tables Table 1 Patient characteristics Characteristics N Patient No. 35 Age (years) Median (range) 52.1 ± 13.5 (26–76) Sex Male 10 (28.6%) Female 25 (71.4%) Histopathology SRCC 20 (57.1%) Non-SRCC 15 (42.9%) Grade Moderately/moderately to poorly 8 (22.9%) Poorly 27 (77.1%) T stage T1-2 6 (17.1%) T3-4 29 (82.9%) N stage N0 14 (40%) N+ 21 (60%) M stage M0 10 (28.6%) M1 25 (71.4%) Clinical stage Ⅰ 5 Ⅱ 1 Ⅲ 3 Ⅳ 26 Abbreviations: No., number; SRCC, signet-ring cell carcinoma. Table 2 Diagnostic performance of [ 18 F]-FDG and [ 68 Ga]-FAPI-04 in PET/CT and PET/MR Sensitivity % (n/n) Specificity % (n/n) Accuracy % (n/n) Positive predictive value % (n/n) Negative predictive value % (n/n) [ 18 F]-FDG PET/CT Primary tumor 95.5 (21/22) NA 95.5 (21/22) 100 (21/21) NA Lymph node 69.2 (9/13) 66.7 (6/9) 68.1 (15/22) 75 (9/12) 60 (6/10) Peritoneal 41.7 (5/12) 100 (10/10) 68.2 (15/22) 100 (5/5) 58.8 (10/17) Bone 100 (1/1) 100 (21/21) 100 (22/22) 100 (1/1) 100 (21/21) Ovary 66.7 (2/3) 92.3 (12/13) 87.5 (14/16) 66.7 (2/3) 92.3 (12/13) [ 18 F]-FDG PET/MR Primary tumor 97.1 (33/34) NA 97.1 (33/34) 100 (34/34) NA Lymph node 75 (15/20) 85.7 (12/14) 79.4 (27/34) 88.2 (15/17) 70.6 (12/17) Peritoneal 66.7 (14/21) 100 (13/13) 79.4 (27/34) 100 (14/14) 65 (13/20) Bone 100 (3/3) 100 (31/31) 100 (34/34) 100 (3/3) 100 (31/31) Ovary 100 (5/5) 94.7 (18/19) 95.8 (23/24) 83.3 (5/6) 100 (18/18) [ 68 Ga]-FAPI PET/CT Primary tumor 97.1 (34/35) NA 97.1 (34/35) 100 (35/35) NA Lymph node 85.7 (18/21) 100 (14/14) 91.4 (32/35) 100 (18/18) 82.3 (14/17) Peritoneal 95.2 (20/21) 100 (14/14) 97.1 (34/35) 100 (20/20) 93.3 (14/15) Bone 100 (3/3) 100 (32/32) 100 (35/35) 100 (3/3) 100 (32/32) Ovary 100 (5/5) 100 (20/20) 100 (25/25) 100 (5/5) 100 (20/20) [ 68 Ga]-FAPI PET/MR Primary tumor 97.1 (34/35) NA 97.1 (34/35) 100 (35/35) NA Lymph node 85.7 (18/21) 100 (14/14) 91.4 (32/35) 100 (18/18) 82.3 (14/17) Peritoneal 100 (21/21) 100 (14/14) 100 (35/35) 100 (21/21) 100 (14/14) Bone 100 (3/3) 100 (32/32) 100 (35/35) 100 (3/3) 100 (32/32) Ovary 100 (5/5) 100 (20/20) 100 (25/25) 100 (5/5) 100 (20/20) Note: NA, not applicable. Table 3 Comparison of N-staging results between [ 18 F]-FDG and [ 68 Ga]-FAPI-04 using PET/CT and PET/MR NO. LN (Mets/total) pN stage [ 18 F]-FDG PET/CT [ 18 F]-FDG PET/MR [ 68 Ga]-FAPI PET/CT [ 68 Ga]-FAPI PET/MR TP FP TN FN N stage Effect TP FP TN FN N stage Effect TP FP TN FN N stage Effect TP FP TN FN N stage Effect 1 12/28 3a 0 0 16 12 0 ↓ 1 0 16 11 1 ↓ 3 0 16 9 2 ↓ 3 0 16 9 2 ↓ 2 17/57 3b 5 0 40 12 2 ↓ 5 0 40 12 2 ↓ 5 0 40 12 2 ↓ 5 0 40 12 2 ↓ 3 12/28 3a 5 0 16 7 2 ↓ 5 0 16 7 2 ↓ 5 0 16 7 2 ↓ 5 0 16 17 2 ↓ 4 27/49 3a 0 0 22 27 0 ↓ 0 0 22 27 0 ↓ 0 0 22 27 0 ↓ 0 0 22 27 0 ↓ 5 0/32 0 0 2 30 0 1 ↑ 0 2 30 0 1 ↑ 0 0 32 0 0 → 0 0 32 0 0 → 6 3/30 2 3 0 27 0 2 → 3 0 27 0 2 → 3 0 27 0 2 → 3 0 27 0 2 → 7 3/56 2 0 0 53 3 0 ↓ 0 0 53 3 0 ↓ 0 0 53 3 0 ↓ 0 0 53 3 0 ↓ 8 0/61 0 0 2 59 0 1 ↑ 0 1 60 0 1 ↑ 0 0 61 0 0 → 0 0 61 0 0 → 9 0/30 0 0 0 30 0 0 → 0 0 30 0 0 → 0 0 30 0 0 → 0 0 30 0 0 → 10 0/37 0 0 1 36 0 0 → 0 0 37 0 0 → 0 0 37 0 0 → 0 0 37 0 0 → 11 1/20 1 0 0 19 1 0 ↓ 0 0 19 1 0 ↓ 1 0 19 0 1 → 1 0 19 0 1 → 12 7/40 3a 2 0 33 5 1 ↓ 3 0 33 4 2 ↓ 4 0 33 3 2 ↓ 4 0 33 3 2 ↓ 13 12/27 3a 4 0 15 8 2 ↓ 4 0 15 8 2 ↓ 4 0 15 8 2 ↓ 4 0 15 8 2 ↓ 14 0/35 0 0 0 35 0 0 → 0 0 35 0 0 → 0 0 35 0 0 → 0 0 35 0 0 → 94/530 19 5 431 75 21 3 433 73 25 0 436 69 25 0 436 69 Abbreviations: No., number; LN, lymph node(s); Mets, metastases; Total, total number of resected lymph nodes; pN stage, N-staging according to postoperative pathological results; N stage, N-staging according to imaging modality results. Symbols: →, unchanged (concordant); ↑, overestimated; ↓, underestimated. Definitions: TP, true positive; FP, false positive; TN, true negative; FN, false negative. Additional Declarations No competing interests reported. Cite Share Download PDF Status: Published Journal Publication published 20 Apr, 2026 Read the published version in Abdominal Radiology → Version 1 posted Editorial decision: Revision requested 13 Mar, 2026 Reviews received at journal 13 Mar, 2026 Reviewers agreed at journal 04 Mar, 2026 Reviews received at journal 04 Mar, 2026 Reviewers agreed at journal 24 Feb, 2026 Reviewers invited by journal 23 Feb, 2026 Editor assigned by journal 22 Feb, 2026 Submission checks completed at journal 22 Feb, 2026 First submitted to journal 22 Feb, 2026 You are reading this latest preprint version Research Square lets you share your work early, gain feedback from the community, and start making changes to your manuscript prior to peer review in a journal. As a division of Research Square Company, we’re committed to making research communication faster, fairer, and more useful. We do this by developing innovative software and high quality services for the global research community. Our growing team is made up of researchers and industry professionals working together to solve the most critical problems facing scientific publishing. Also discoverable on Platform About Our Team In Review Editorial Policies Advisory Board Help Center Resources Author Services Accessibility API Access RSS feed Manage Cookie Preferences © Research Square 2026 | ISSN 2693-5015 (online) Privacy Policy Terms of Service Do Not Sell My Personal Information {\"props\":{\"pageProps\":{\"initialData\":{\"identity\":\"rs-8937576\",\"acceptedTermsAndConditions\":true,\"allowDirectSubmit\":false,\"archivedVersions\":[],\"articleType\":\"Research Article\",\"associatedPublications\":[],\"authors\":[{\"id\":597130768,\"identity\":\"38f14b80-37bd-42af-9aad-0246cc811eef\",\"order_by\":0,\"name\":\"Zhenghao Jiang\",\"email\":\"\",\"orcid\":\"\",\"institution\":\"Zhongshan Hospital, Fudan University\",\"correspondingAuthor\":false,\"prefix\":\"\",\"firstName\":\"Zhenghao\",\"middleName\":\"\",\"lastName\":\"Jiang\",\"suffix\":\"\"},{\"id\":597130770,\"identity\":\"1df69c2e-a2c7-448d-bb00-8d0e19155705\",\"order_by\":1,\"name\":\"Lifang Pang\",\"email\":\"\",\"orcid\":\"\",\"institution\":\"Zhongshan Hospital, Fudan University\",\"correspondingAuthor\":false,\"prefix\":\"\",\"firstName\":\"Lifang\",\"middleName\":\"\",\"lastName\":\"Pang\",\"suffix\":\"\"},{\"id\":597130773,\"identity\":\"09619a22-be15-4f91-af02-9c6c6f30684e\",\"order_by\":2,\"name\":\"Yihan Yan\",\"email\":\"\",\"orcid\":\"\",\"institution\":\"Zhongshan Hospital, Fudan University\",\"correspondingAuthor\":false,\"prefix\":\"\",\"firstName\":\"Yihan\",\"middleName\":\"\",\"lastName\":\"Yan\",\"suffix\":\"\"},{\"id\":597130774,\"identity\":\"30b78737-2f04-4ae2-a9cb-4703473ac6f3\",\"order_by\":3,\"name\":\"Masong Tang\",\"email\":\"\",\"orcid\":\"\",\"institution\":\"Zhongshan Hospital, Fudan University\",\"correspondingAuthor\":false,\"prefix\":\"\",\"firstName\":\"Masong\",\"middleName\":\"\",\"lastName\":\"Tang\",\"suffix\":\"\"},{\"id\":597130777,\"identity\":\"c5e17f34-e16a-4114-bf00-ec69512458bd\",\"order_by\":4,\"name\":\"Yiqiu Zhang\",\"email\":\"data:image/png;base64,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\",\"orcid\":\"\",\"institution\":\"Zhongshan Hospital, Fudan University\",\"correspondingAuthor\":true,\"prefix\":\"\",\"firstName\":\"Yiqiu\",\"middleName\":\"\",\"lastName\":\"Zhang\",\"suffix\":\"\"}],\"badges\":[],\"createdAt\":\"2026-02-22 07:38:11\",\"currentVersionCode\":1,\"declarations\":\"\",\"doi\":\"10.21203/rs.3.rs-8937576/v1\",\"doiUrl\":\"https://doi.org/10.21203/rs.3.rs-8937576/v1\",\"draftVersion\":[],\"editorialEvents\":[{\"content\":\"https://doi.org/10.1007/s00261-026-05517-x\",\"type\":\"published\",\"date\":\"2026-04-20T15:57:53+00:00\"}],\"editorialNote\":\"\",\"failedWorkflow\":false,\"files\":[{\"id\":103576045,\"identity\":\"3f70c5fd-eb54-41f0-b116-63381690aa10\",\"added_by\":\"auto\",\"created_at\":\"2026-02-27 09:12:35\",\"extension\":\"jpg\",\"order_by\":1,\"title\":\"Figure 1\",\"display\":\"\",\"copyAsset\":false,\"role\":\"figure\",\"size\":95424,\"visible\":true,\"origin\":\"\",\"legend\":\"\\u003cp\\u003e\\u003cstrong\\u003eFlowchart illustrating the patient enrollment and selection process.\\u003c/strong\\u003e\\u003c/p\\u003e\",\"description\":\"\",\"filename\":\"1.jpg\",\"url\":\"https://assets-eu.researchsquare.com/files/rs-8937576/v1/1a73ae9d705e20fe42de588b.jpg\"},{\"id\":103576040,\"identity\":\"9610e9ae-b7a8-406a-8e36-11f606cbb356\",\"added_by\":\"auto\",\"created_at\":\"2026-02-27 09:12:34\",\"extension\":\"jpg\",\"order_by\":2,\"title\":\"Figure 2\",\"display\":\"\",\"copyAsset\":false,\"role\":\"figure\",\"size\":80298,\"visible\":true,\"origin\":\"\",\"legend\":\"\\u003cp\\u003e\\u003cstrong\\u003eComparison of radiotracer uptake in gastric cancer lesions across different anatomical sites and imaging modalities.\\u003c/strong\\u003e\\u003c/p\\u003e\\n\\u003cp\\u003eData are presented as means with upper and lower limits. *\\u003cem\\u003eP\\u003c/em\\u003e \\u0026lt; 0.05, **\\u003cem\\u003eP\\u003c/em\\u003e \\u0026lt; 0.01, ***\\u003cem\\u003eP\\u003c/em\\u003e \\u0026lt; 0.001 (independent Student’s t-test, two-sided).\\u003c/p\\u003e\",\"description\":\"\",\"filename\":\"2.jpg\",\"url\":\"https://assets-eu.researchsquare.com/files/rs-8937576/v1/e4db7f785c0b372c63364a6d.jpg\"},{\"id\":103576042,\"identity\":\"a976fd4f-394a-4727-aa20-709101518bb5\",\"added_by\":\"auto\",\"created_at\":\"2026-02-27 09:12:34\",\"extension\":\"jpg\",\"order_by\":3,\"title\":\"Figure 3\",\"display\":\"\",\"copyAsset\":false,\"role\":\"figure\",\"size\":102576,\"visible\":true,\"origin\":\"\",\"legend\":\"\\u003cp\\u003e26-year-old female with poorly differentiated gastric cancer (endoscopic biopsy-proven) who underwent staging PET/CT and PET/MR. [68Ga]-FAPI-04 PET/CT and PET/MR show tracer uptake in the primary tumor and intense activity in regional lymph nodes (red arrows); [18F]-FDG PET/MR shows no nodal tracer uptake.\\u003c/p\\u003e\",\"description\":\"\",\"filename\":\"3.jpg\",\"url\":\"https://assets-eu.researchsquare.com/files/rs-8937576/v1/286b3f65e47abc962475c7ac.jpg\"},{\"id\":103576094,\"identity\":\"47834a78-34a6-4131-8141-2333e3dd2326\",\"added_by\":\"auto\",\"created_at\":\"2026-02-27 09:12:37\",\"extension\":\"jpg\",\"order_by\":4,\"title\":\"Figure 4\",\"display\":\"\",\"copyAsset\":false,\"role\":\"figure\",\"size\":101079,\"visible\":true,\"origin\":\"\",\"legend\":\"\\u003cp\\u003e33-year-old female with signet ring cell gastric cancer (endoscopic biopsy-proven) who underwent staging PET/CT and PET/MR. [68Ga]-FAPI-04 PET/CT and PET/MR demonstrate tracer accumulation in the primary lesion (red arrows) and peritoneal lesions (white arrows); [18F]-FDG PET/CT and PET/MR show no such tracer uptake.\\u003c/p\\u003e\",\"description\":\"\",\"filename\":\"4.jpg\",\"url\":\"https://assets-eu.researchsquare.com/files/rs-8937576/v1/b774032c947502e4bf43933f.jpg\"},{\"id\":107929332,\"identity\":\"e490690c-bcab-48dd-b893-7d7d274df426\",\"added_by\":\"auto\",\"created_at\":\"2026-04-27 16:14:50\",\"extension\":\"pdf\",\"order_by\":0,\"title\":\"\",\"display\":\"\",\"copyAsset\":false,\"role\":\"manuscript-pdf\",\"size\":1021357,\"visible\":true,\"origin\":\"\",\"legend\":\"\",\"description\":\"\",\"filename\":\"manuscript.pdf\",\"url\":\"https://assets-eu.researchsquare.com/files/rs-8937576/v1/efcf361b-b1c0-4765-b552-b3afb97b513c.pdf\"}],\"financialInterests\":\"No competing interests reported.\",\"formattedTitle\":\"[68Ga]-FAPI-04 outperforms [18F]-FDG in gastric cancer staging: a comparative study using PET/CT and PET/MR\",\"fulltext\":[{\"header\":\"Key Points\",\"content\":\"\\u003cp\\u003e\\u003cstrong\\u003eQuestion\\u0026nbsp;\\u003c/strong\\u003eAccurate staging of gastric cancer, especially for FDG-insensitive subtypes and peritoneal metastases, remains clinically challenging.\\u003c/p\\u003e\\n\\u003cp\\u003e\\u003cstrong\\u003eFindings\\u003c/strong\\u003e [\\u003csup\\u003e68\\u003c/sup\\u003eGa]-FAPI-04 PET/CT and PET/MR outperforms [\\u003csup\\u003e18\\u003c/sup\\u003eF]-FDG in detecting primary tumors, lymph node, and peritoneal metastases of gastric cancer.\\u003c/p\\u003e\\n\\u003cp\\u003e\\u003cstrong\\u003eClinical Relevance\\u0026nbsp;\\u003c/strong\\u003e[\\u003csup\\u003e68\\u003c/sup\\u003eGa]-FAPI-04 combined with PET/MR optimizes gastric cancer staging, aiding personalized treatment decisions for FDG-insensitive subtypes and peritoneal metastases.\\u003c/p\\u003e\"},{\"header\":\"Introduction\",\"content\":\"\\u003cp\\u003eGastric cancer is the fifth most common malignancy and a leading cause of cancer-related death worldwide\\u0026nbsp;[1]. Accurate staging is critical for personalized treatment as it directly impacts prognosis [2] , but precise preoperative staging remains a clinical challenge.\\u003c/p\\u003e\\n\\u003cp\\u003eCurrent staging relies on multimodal imaging. Endoscopy is the diagnostic cornerstone, while CT is the primary modality for distant metastasis evaluation [2]. However, CT has limitations in local T-stage assessment, lymph node detection, and peritoneal metastasis identification [3].\\u0026nbsp;\\u003c/p\\u003e\\n\\u003cp\\u003e[\\u003csup\\u003e18\\u003c/sup\\u003eF]-fluorodeoxyglucose ([\\u003csup\\u003e18\\u003c/sup\\u003eF]-FDG) PET/CT is recommended for occult metastasis detection before curative treatment [4]. Nevertheless, it has intrinsic drawbacks: low metabolic activity causes false negatives in subtypes like signet-ring cell carcinoma (SRCC) [5], and physiological abdominal uptake compromises peritoneal metastasis accuracy [6].\\u003c/p\\u003e\\n\\u003cp\\u003eGallium-68\\u0026ndash;labeled fibroblast activation protein inhibitor-04 ([\\u003csup\\u003e68\\u003c/sup\\u003eGa]-FAPI-04) is a novel stroma-targeted radiotracer binding to fibroblast activation protein (FAP) [7], a promising imaging target. Preliminary evidence shows it outperforms [\\u003csup\\u003e18\\u003c/sup\\u003eF]-FDG PET/CT in detecting gastric cancer lesions [8] , but most studies are limited to PET/CT alone.\\u003c/p\\u003e\\n\\u003cp\\u003eIn contrast, MR provides superior soft-tissue contrast, benefiting local T-staging and peritoneal assessment [9]. To date, systematic comparisons of both radiotracers across PET/CT and PET/MR for gastric cancer staging are scarce. Thus, this study aims to comprehensively compare the diagnostic performance of [\\u003csup\\u003e68\\u003c/sup\\u003eGa]-FAPI-04 and [\\u003csup\\u003e18\\u003c/sup\\u003eF]-FDG in detecting primary and metastatic gastric cancer lesions using both modalities.\\u003c/p\\u003e\"},{\"header\":\"Materials and methods\",\"content\":\"\\u003cp\\u003e\\u003cstrong\\u003ePatient enrollment\\u003c/strong\\u003e\\u003c/p\\u003e\\n\\u003cp\\u003eThis single-center retrospective study was conducted at Zhongshan Hospital, Fudan University. The study protocol was approved by the Institutional Review Board (IRB; No. B2022-098R2), and written informed consent was obtained from each patient. Between May 2022 and May 2025, patients who underwent sequential PET imaging with [\\u003csup\\u003e68\\u003c/sup\\u003eGa]-FAPI-04 and [\\u003csup\\u003e18\\u003c/sup\\u003eF]-FDG within a 48-hour window were retrospectively enrolled. For [\\u003csup\\u003e68\\u003c/sup\\u003eGa]-FAPI-04 imaging, both PET/CT and PET/MR data were acquired concurrently. In contrast, [\\u003csup\\u003e18\\u003c/sup\\u003eF]-FDG imaging comprised PET/CT, PET/MR, or both modalities. The inclusion criteria were as follows: (a) histological diagnosis of gastric cancer; (b) completion of paired [\\u003csup\\u003e18\\u003c/sup\\u003eF]-FDG and [\\u003csup\\u003e68\\u003c/sup\\u003eGa]-FAPI-04 PET/CT and PET/MR for tumor staging to determine the optimal treatment strategy; and (c) provision of written informed consent. The exclusion criteria were: (a) prior anti-tumor therapy; (b) presence of concomitant malignant neoplasms; and (c) insufficient clinical or follow-up data.\\u003c/p\\u003e\\n\\u003cp\\u003e\\u003cstrong\\u003ePreparation of [\\u003csup\\u003e18\\u003c/sup\\u003eF]-FDG and [\\u003csup\\u003e68\\u003c/sup\\u003eGa]-FAPI-04\\u003c/strong\\u003e\\u003c/p\\u003e\\n\\u003cp\\u003e[\\u003csup\\u003e18\\u003c/sup\\u003eF]-FDG was synthesized following the standard institutional protocol using an [\\u003csup\\u003e18\\u003c/sup\\u003eF]-FDG synthesis module (PET-FDG-IT-NA; PET Technology Co., Ltd., Beijing, China). The FAPI precursor, 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA)-conjugated FAPI-04, was obtained from Huayi Technology Co., Ltd. (Jiangsu, China). Radiolabeling of DOTA-FAPI-04 was performed by combining 100 \\u0026mu;g of the precursor with 1 mL of 0.25 M sodium acetate and 4 mL of \\u003csup\\u003e68\\u003c/sup\\u003eGa solution (370 MBq in 0.05 M HCl). The reaction mixture was incubated at 95\\u0026deg;C for 10 minutes, yielding a final pH of approximately 6.0. Radio-high-performance liquid chromatography (R-HPLC) analysis confirmed that the radiochemical yields of both [\\u003csup\\u003e18\\u003c/sup\\u003eF]-FDG and [\\u003csup\\u003e68\\u003c/sup\\u003eGa]-DOTA-FAPI-04 exceeded 90%. Finally, both tracers were diluted with saline and sterilized by passage through a 0.22-\\u0026mu;m filter (Millipore, Billerica, MA, USA) into a sterile syringe. R-HPLC verified that the radiochemical purity of both tracers was greater than 98%.\\u003c/p\\u003e\\n\\u003cp\\u003e\\u003cstrong\\u003ePET/MR and PET/CT scan protocols\\u003c/strong\\u003e\\u003c/p\\u003e\\n\\u003cp\\u003ePatients underwent PET imaging with [\\u003csup\\u003e68\\u003c/sup\\u003eGa]-FAPI-04 and\\u0026nbsp;[\\u003csup\\u003e18\\u003c/sup\\u003eF]-FDG within a 48-hour window. Following intravenous administration of [\\u003csup\\u003e68\\u003c/sup\\u003eGa]-FAPI-04 (1.85\\u0026ndash;3.70 MBq/kg), whole-body PET/MR (uPMR 790 HD TOF PET/MR system; United Imaging Healthcare, Shanghai, China) and PET/CT (uEXPLORER; United Imaging Healthcare) were performed sequentially approximately 30\\u0026ndash;60 minutes post-injection, with a median interval of 82 minutes (range: 49\\u0026ndash;143 minutes) between scans. Patients fasted for at least 6 hours prior to the administration of [\\u003csup\\u003e18\\u003c/sup\\u003eF]-FDG (3.7 MBq/kg), and blood glucose levels were maintained below 11.0 mmol/L. Approximately 60 minutes after [\\u003csup\\u003e18\\u003c/sup\\u003eF]-FDG injection, PET/CT, PET/MR, or both were performed. If both scans were conducted, PET/MR was performed first, followed by PET/CT, with a median interval of 71 minutes (range: 49\\u0026ndash;106 minutes).\\u003c/p\\u003e\\n\\u003cp\\u003eA low-dose CT scan (5\\u0026ndash;10 mAs, 120 kV) was acquired first for attenuation correction (AC), followed by a diagnostic free-breathing CT scan using modulated tube current and voltage (120 kV for the body; 258 mAs and 120 kV for the head). Static PET images were acquired over 10 minutes and reconstructed using the ordered subset expectation maximization algorithm (slice thickness, 1.443 mm; 3 iterations; 20 subsets; matrix, 192 \\u0026times; 192).\\u0026nbsp;\\u003c/p\\u003e\\n\\u003cp\\u003ePET/MR imaging included a whole-body scan and a dedicated abdominal scan. Patients were positioned using dedicated whole-body and head coils. Earplugs were provided to minimize gradient noise, and foam wedges were used to stabilize the head. For magnetic resonance attenuation correction (MRAC), a 3D T1-weighted spoiled gradient-echo sequence combined with Dixon-based water-fat separation imaging (WFI) was acquired in the coronal plane (repetition time [TR] = 4.6 ms; echo time [TE] = 3.2 ms; slice thickness = 2.4 mm; field of view [FOV] = 500 \\u0026times; 350 mm; matrix = 206 \\u0026times; 144; acquisition time = 31 seconds). Compressed sensing technology was employed to accelerate data acquisition. Tissue segmentation and attenuation coefficient map (\\u0026mu;-map) calculation were automatically performed via the vendor-supplied algorithm. Whole-body PET data were acquired in 3D list mode with five bed positions (average acquisition time: 3 minutes per bed; overlap: 30%) covering the region from the skull base to the proximal thighs.\\u003c/p\\u003e\\n\\u003cp\\u003e\\u003cstrong\\u003eImage analysis\\u003c/strong\\u003e\\u003c/p\\u003e\\n\\u003cp\\u003eAll [\\u003csup\\u003e18\\u003c/sup\\u003eF]-FDG and [\\u003csup\\u003e68\\u003c/sup\\u003eGa]-FAPI-04 PET/CT and PET/MR images were independently reviewed and interpreted by two experienced nuclear medicine physicians using a dedicated United Imaging workstation (United Imaging Healthcare, Shanghai, China), with final interpretations reached by consensus. A primary or metastatic lesion was considered positive when focal tracer uptake exceeded background activity and corresponded to abnormal findings on CT or MR images, after exclusion of potential confounders such as physiological uptake, trauma, infection, or inflammation. For peritoneal metastases, CT and MR images were jointly evaluated to differentiate diffuse pathological involvement from physiological intestinal uptake and to distinguish nodular peritoneal lesions from hypermetabolic lymph nodes. For suspected bone metastases, CT and MR findings were used to exclude benign conditions, including Schmorl\\u0026rsquo;s nodes, hyperostosis, and degenerative changes.\\u003c/p\\u003e\\n\\u003cp\\u003eSemi-quantitative analysis was performed by manually delineating regions of interest (ROIs) along the lesion margins on axial images. The maximum standardized uptake value (SUV\\u003csub\\u003emax\\u003c/sub\\u003e) was automatically calculated by the system. The target-to-background ratio (TBR) was defined as the ratio of lesion SUV\\u003csub\\u003emax\\u003c/sub\\u003e to the mean standardized uptake value of normal liver tissue.\\u003c/p\\u003e\\n\\u003cp\\u003ePET/CT and PET/MR findings were validated against histopathological results obtained from gastroscopy or surgical specimens. When histopathological confirmation was unavailable, clinical follow-up data, including laboratory results and serial imaging findings over a minimum period of three months, were used as a reference standard. Tumors were staged according to the 8th Edition of the American Joint Committee on Cancer (AJCC) Cancer Staging Manual.\\u003c/p\\u003e\\n\\u003cp\\u003e\\u003cstrong\\u003eStatistical analysis\\u003c/strong\\u003e\\u003c/p\\u003e\\n\\u003cp\\u003eStatistical analyses were performed using SPSS software (version 27.0.1; IBM Corp., Armonk, NY, USA). Continuous variables were summarized as mean \\u0026plusmn; standard deviation (SD), and categorical variables were presented as counts and percentages. The Wilcoxon signed-rank test was applied to evaluate differences in SUV\\u003csub\\u003emax\\u003c/sub\\u003e and TBR between groups, and McNemar\\u0026apos;s test was used to compare diagnostic performance. A two-tailed \\u003cem\\u003eP\\u003c/em\\u003e-value \\u0026lt; 0.05 was considered statistically significant.\\u003c/p\\u003e\"},{\"header\":\"Results\",\"content\":\"\\u003cp\\u003e\\u003cstrong\\u003ePatient characteristics\\u003c/strong\\u003e\\u003c/p\\u003e\\n\\u003cp\\u003eThe study design is illustrated in Fig. 1. A total of 35 patients with pathologically confirmed gastric cancer, diagnosed by surgical resection or gastroscopic biopsy, were included in the analysis. All patients underwent [\\u003csup\\u003e68\\u003c/sup\\u003eGa]-FAPI PET/CT and PET/MR. Among them, 21 patients underwent both [\\u003csup\\u003e18\\u003c/sup\\u003eF]-FDG PET/CT and PET/MR, 13 underwent only [\\u003csup\\u003e18\\u003c/sup\\u003eF]-FDG PET/MR, and 1 underwent only [\\u003csup\\u003e18\\u003c/sup\\u003eF]-FDG PET/CT. According to imaging-based staging, 18 patients with early-stage disease proceeded to surgical resection, whereas the remaining 17 patients received systemic treatment, including chemotherapy, immunotherapy, or targeted therapy. Detailed patient characteristics are summarized in Table 1.\\u003c/p\\u003e\\n\\u003cp\\u003e\\u003cstrong\\u003eComparison of [\\u003csup\\u003e68\\u003c/sup\\u003eGa]-FAPI-04 and [\\u003csup\\u003e18\\u003c/sup\\u003eF]-FDG in the detection of primary tumors\\u003c/strong\\u003e\\u003c/p\\u003e\\n\\u003cp\\u003eA total of 35 patients with 35 evaluable primary lesions were included in the primary lesion analysis. The mean depth of primary gastric cancer lesions was 16.1 \\u0026plusmn; 5.6 mm (range, 4.1\\u0026ndash;33.8 mm). The diagnostic performance of [\\u003csup\\u003e68\\u003c/sup\\u003eGa]-FAPI-04 and [\\u003csup\\u003e18\\u003c/sup\\u003eF]-FDG using PET/CT and PET/MR is summarized in Table 2.\\u003c/p\\u003e\\n\\u003cp\\u003eIn patient-based analyses, [\\u003csup\\u003e68\\u003c/sup\\u003eGa]-FAPI-04 PET/CT and PET/MR each achieved a primary tumor detection rate of 97.1% (34/35). For [\\u003csup\\u003e18\\u003c/sup\\u003eF]-FDG, detection rates were 95.5% (21/22) with PET/CT and 97.1% (33/34) with PET/MR, with no statistically significant differences observed among the four modalities (all \\u003cem\\u003ep=\\u003c/em\\u003e1.000). The single lesion missed by all modalities was pathologically confirmed as SRCC confined to the lamina propria and was also negative on both CT and MR.\\u003c/p\\u003e\\n\\u003cp\\u003eWhen comparing tracers on the same imaging platform, [\\u003csup\\u003e68\\u003c/sup\\u003eGa]-FAPI-04 demonstrated significantly higher tracer uptake than [\\u003csup\\u003e18\\u003c/sup\\u003eF]-FDG on both PET/CT (SUV\\u003csub\\u003emax\\u003c/sub\\u003e: 11.18 \\u0026plusmn; 5.32 vs. 3.79 \\u0026plusmn; 2.03, \\u003cem\\u003ep\\u003c/em\\u003e＜0.001) and PET/MR (SUV\\u003csub\\u003emax\\u003c/sub\\u003e: 9.39 \\u0026plusmn; 4.42 vs. 3.37 \\u0026plusmn; 2.23, \\u003cem\\u003ep\\u003c/em\\u003e＜0.001). Correspondingly, TBR values were significantly higher for [\\u003csup\\u003e68\\u003c/sup\\u003eGa]-FAPI-04 than for [\\u003csup\\u003e18\\u003c/sup\\u003eF]-FDG on PET/CT (13.81 \\u0026plusmn; 10.00 vs. 2.04 \\u0026plusmn; 1.02, \\u003cem\\u003ep\\u003c/em\\u003e\\u003cem\\u003e＜\\u003c/em\\u003e0.001) and PET/MR (16.35 \\u0026plusmn; 13.34 vs. 2.18 \\u0026plusmn; 1.28, \\u003cem\\u003ep\\u003c/em\\u003e＜0.001).\\u003c/p\\u003e\\n\\u003cp\\u003eWhen comparing the same tracer across imaging platforms, [\\u003csup\\u003e18\\u003c/sup\\u003eF]-FDG PET/CT yielded slightly higher SUV\\u003csub\\u003emax\\u003c/sub\\u003e than PET/MR (3.79 \\u0026plusmn; 2.03 vs. 3.37 \\u0026plusmn; 2.23, \\u003cem\\u003ep=\\u003c/em\\u003e 0.010), with no significant difference in TBR (\\u003cem\\u003ep=\\u003c/em\\u003e 0.476). Similarly, [\\u003csup\\u003e68\\u003c/sup\\u003eGa]-FAPI-04 PET/CT showed higher SUV\\u003csub\\u003emax\\u003c/sub\\u003e than PET/MR (11.18 \\u0026plusmn; 5.32 vs. 9.39 \\u0026plusmn; 4.42, \\u003cem\\u003ep\\u003c/em\\u003e＜0.001), whereas PET/MR demonstrated a significantly higher TBR than PET/CT (16.35 \\u0026plusmn; 13.34 vs. 13.81 \\u0026plusmn; 10.00, \\u003cem\\u003ep=\\u003c/em\\u003e0.020) (Fig. 2).\\u003c/p\\u003e\\n\\u003cp\\u003ePathological analysis identified SRCC in 20 of 35 patients. In the SRCC subgroup, both SUV\\u003csub\\u003emax\\u003c/sub\\u003e and TBR of [\\u003csup\\u003e68\\u003c/sup\\u003eGa]-FAPI-04 were significantly higher than those of [\\u003csup\\u003e18\\u003c/sup\\u003eF]-FDG on PET/CT (SUV\\u003csub\\u003emax\\u003c/sub\\u003e: 10.20 \\u0026plusmn; 5.62 vs. 3.06 \\u0026plusmn; 2.82, \\u003cem\\u003ep=\\u003c/em\\u003e 0.001; TBR: 11.33 \\u0026plusmn; 7.90 vs. 1.71 \\u0026plusmn; 0.83, \\u003cem\\u003ep\\u003c/em\\u003e＜0.001) and PET/MR (SUV\\u003csub\\u003emax\\u003c/sub\\u003e: 8.37 \\u0026plusmn; 4.11 vs. 2.66 \\u0026plusmn; 1.37, \\u003cem\\u003ep\\u003c/em\\u003e＜0.001; TBR: 12.91 \\u0026plusmn; 9.93 vs. 1.73 \\u0026plusmn; 0.92, \\u003cem\\u003ep\\u003c/em\\u003e＜0.001). Similar findings were observed in the non-SRCC subgroup, in which [\\u003csup\\u003e68\\u003c/sup\\u003eGa]-FAPI-04 also demonstrated significantly higher SUV\\u003csub\\u003emax\\u003c/sub\\u003e and TBR than [\\u003csup\\u003e18\\u003c/sup\\u003eF]-FDG across both modalities (all \\u003cem\\u003ep\\u003c/em\\u003e＜0.05). Significant differences in [\\u003csup\\u003e18\\u003c/sup\\u003eF]-FDG uptake were observed between the non-SRCC and SRCC groups, including PET/CT SUV\\u003csub\\u003emax\\u003c/sub\\u003e (U = 26.0, \\u003cem\\u003ep=\\u003c/em\\u003e0.040), PET/MR SUV\\u003csub\\u003emax\\u003c/sub\\u003e (U = \\u003csup\\u003e68\\u003c/sup\\u003e.0, \\u003cem\\u003ep=\\u003c/em\\u003e0.012), and corresponding TBR values (\\u003cem\\u003ep=\\u003c/em\\u003e0.041 and \\u003cem\\u003ep=\\u003c/em\\u003e0.005, respectively). In contrast, no significant differences were detected between the two histological subgroups for any [\\u003csup\\u003e68\\u003c/sup\\u003eGa]-FAPI-04 uptake parameters on either imaging platform (all \\u003cem\\u003ep\\u003c/em\\u003e \\u0026gt; 0.05).\\u003c/p\\u003e\\n\\u003cp\\u003e\\u003cstrong\\u003eComparison of [\\u003csup\\u003e68\\u003c/sup\\u003eGa]-FAPI-04 and [\\u003csup\\u003e18\\u003c/sup\\u003eF]-FDG in the detection of lymph nodal metastases\\u003c/strong\\u003e\\u003c/p\\u003e\\n\\u003cp\\u003eAmong the 35 patients included in the analysis, 21 were confirmed to have regional lymph node metastases based on histopathological findings or clinical follow-up. The diagnostic performance of the different imaging modalities is summarized in Table 2. In patient-based comparisons, only [\\u003csup\\u003e68\\u003c/sup\\u003eGa]-FAPI-04 PET/MR demonstrated a statistically significant advantage over [\\u003csup\\u003e18\\u003c/sup\\u003eF]-FDG PET/MR (\\u0026chi;\\u003csup\\u003e2\\u003c/sup\\u003e = 7.11, \\u003cem\\u003ep=\\u003c/em\\u003e 0.008). No significant differences were observed in the remaining pairwise comparisons between imaging modalities (all \\u003cem\\u003ep\\u003c/em\\u003e \\u0026gt;0.05). Lesion-based analysis of lymph node metastases was not fully feasible, as histopathological confirmation was unavailable for all evaluated lymph nodes, precluding comprehensive assessment of diagnostic efficacy at the lesion level.\\u003c/p\\u003e\\n\\u003cp\\u003eAs illustrated in Fig. 3, a 26-year-old female with poorly differentiated gastric cancer (endoscopic biopsy-proven) showed intense tracer uptake in regional lymph nodes (red arrows) on [\\u003csup\\u003e68\\u003c/sup\\u003eGa]-FAPI-04 PET/CT and PET/MR, while [\\u003csup\\u003e18\\u003c/sup\\u003eF]-FDG PET/MR showed negative nodal findings. Lymph node enlargement relative to the baseline on 6-month follow-up CT imaging corroborated the lymph node-positive findings of [\\u003csup\\u003e68\\u003c/sup\\u003eGa]-FAPI-04 imaging.\\u003c/p\\u003e\\n\\u003cp\\u003e\\u003cstrong\\u003eAnalysis of patients who received lymphadenectomy\\u003c/strong\\u003e\\u003c/p\\u003e\\n\\u003cp\\u003eAmong the 18 patients who underwent lymphadenectomy, 14 completed all four imaging examinations. A total of 530 lymph nodes were dissected, of which 94 metastatic nodes were identified in 9 patients. N-staging results based on [\\u003csup\\u003e18\\u003c/sup\\u003eF]-FDG and [\\u003csup\\u003e68\\u003c/sup\\u003eGa]-FAPI-04 PET/CT and PET/MR are summarized in Table 3. In patient-based analyses, [\\u003csup\\u003e18\\u003c/sup\\u003eF]-FDG PET/CT correctly classified 8 cases; two cases with increased FDG uptake were pathologically confirmed as false positives, and the remaining misclassified cases were attributable to false-negative findings. [\\u003csup\\u003e18\\u003c/sup\\u003eF]-FDG PET/MR correctly classified 9 cases and misclassified 5 cases. In contrast, both [\\u003csup\\u003e68\\u003c/sup\\u003eGa]-FAPI-04 PET/CT and PET/MR correctly classified 12 cases and misclassified 2 cases. Using histopathology as the reference standard, [\\u003csup\\u003e68\\u003c/sup\\u003eGa]-FAPI-04 PET/CT and PET/MR accurately predicted N stage in 50.0% (7/14) of patients, with underestimation in the remaining 50.0% (7/14). By comparison, [\\u003csup\\u003e18\\u003c/sup\\u003eF]-FDG PET/CT accurately staged 28.6% (4/14) of patients, underestimated N stage in 57.1% (8/14), and overestimated it in 14.3% (2/14). N-staging performance of [\\u003csup\\u003e18\\u003c/sup\\u003eF]-FDG PET/MR was comparable to that of [\\u003csup\\u003e18\\u003c/sup\\u003eF]-FDG PET/CT, with no statistically significant difference (\\u003cem\\u003ep\\u003c/em\\u003e\\u0026gt;0.05).\\u003c/p\\u003e\\n\\u003cp\\u003eLesion-based analysis of the 530 resected lymph nodes showed that [\\u003csup\\u003e18\\u003c/sup\\u003eF]-FDG PET/CT identified 19 true positives, 5 false positives, 431 true negatives, and 75 false negatives, whereas [\\u003csup\\u003e18\\u003c/sup\\u003eF]-FDG PET/MR identified 21 true positives, 3 false positives, 433 true negatives, and 73 false negatives. In contrast, [\\u003csup\\u003e68\\u003c/sup\\u003eGa]-FAPI-04 PET/CT and PET/MR demonstrated identical performance, jointly identifying 25 true positives, no false positives, 436 true negatives, and 69 false negatives. Accordingly, [\\u003csup\\u003e68\\u003c/sup\\u003eGa]-FAPI-04 PET/CT and PET/MR achieved higher sensitivity, specificity, accuracy, PPV, and NPV than [\\u003csup\\u003e18\\u003c/sup\\u003eF]-FDG PET/CT and PET/MR. A statistically significant difference was observed when comparing\\u0026nbsp;[\\u003csup\\u003e68\\u003c/sup\\u003eGa]-FAPI-04 PET/CT or PET/MR with [\\u003csup\\u003e18\\u003c/sup\\u003eF]-FDG PET/CT (\\u0026chi;\\u003csup\\u003e2\\u003c/sup\\u003e = 4.17, \\u003cem\\u003ep=\\u003c/em\\u003e0.041), whereas no significant difference was detected compared with [\\u003csup\\u003e18\\u003c/sup\\u003eF]-FDG PET/MR (\\u0026chi;\\u003csup\\u003e2\\u003c/sup\\u003e = 2.08, \\u003cem\\u003ep=\\u003c/em\\u003e0.149).\\u003c/p\\u003e\\n\\u003cp\\u003eIn semi-quantitative analyses, [\\u003csup\\u003e68\\u003c/sup\\u003eGa]-FAPI-04 PET/CT demonstrated significantly higher SUV\\u003csub\\u003emax\\u003c/sub\\u003e (6.71 \\u0026plusmn; 5.26 vs. 2.81 \\u0026plusmn; 2.50, \\u003cem\\u003ep\\u003c/em\\u003e＜0.001) and TBR (9.33 \\u0026plusmn; 7.90 vs. 1.61 \\u0026plusmn; 1.45, \\u003cem\\u003ep\\u003c/em\\u003e＜0.001) than [\\u003csup\\u003e18\\u003c/sup\\u003eF]-FDG PET/CT. Similar findings were observed for PET/MR, with [\\u003csup\\u003e68\\u003c/sup\\u003eGa]-FAPI-04 showing higher SUV\\u003csub\\u003emax\\u003c/sub\\u003e (5.71 \\u0026plusmn; 3.93 vs. 3.46 \\u0026plusmn; 4.47, \\u003cem\\u003ep\\u003c/em\\u003e＜0.001) and TBR (11.40 \\u0026plusmn; 10.98 vs. 2.03 \\u0026plusmn; 2.31, \\u003cem\\u003ep\\u003c/em\\u003e＜0.001) than [\\u003csup\\u003e18\\u003c/sup\\u003eF]-FDG PET/MR. For the same radiotracer, no significant differences in SUV\\u003csub\\u003emax\\u003c/sub\\u003e or TBR were observed between [\\u003csup\\u003e18\\u003c/sup\\u003eF]-FDG PET/CT and PET/MR (all \\u003cem\\u003ep\\u003c/em\\u003e＞0.05). In contrast, [\\u003csup\\u003e68\\u003c/sup\\u003eGa]-FAPI-04 PET/CT yielded higher SUV\\u003csub\\u003emax\\u003c/sub\\u003e than PET/MR (6.71 \\u0026plusmn; 5.26 vs. 5.71 \\u0026plusmn; 3.93, \\u003cem\\u003ep\\u003c/em\\u003e＜0.001), whereas PET/MR demonstrated a significantly higher TBR than PET/CT (11.40 \\u0026plusmn; 10.98 vs. 9.33 \\u0026plusmn; 7.90, \\u003cem\\u003ep\\u003c/em\\u003e＜0.001) (Fig. 2).\\u003c/p\\u003e\\n\\u003cp\\u003e\\u003cstrong\\u003eComparison of [\\u003csup\\u003e68\\u003c/sup\\u003eGa\\u003c/strong\\u003e\\u003cstrong\\u003e]\\u003c/strong\\u003e\\u003cstrong\\u003e-FAPI-04 and [\\u003csup\\u003e18\\u003c/sup\\u003eF]-FDG in the detection of peritoneal metastasis\\u003c/strong\\u003e\\u003c/p\\u003e\\n\\u003cp\\u003eAmong the 35 patients included in the analysis, 21 were confirmed to have peritoneal metastases based on histopathology or clinical follow-up. Of these, 9 cases were verified by laparoscopic exploration, while the remaining cases were confirmed through follow-up of more than three months, incorporating imaging and serological evidence. The diagnostic performance of the different imaging modalities is summarized in Table 2.\\u003c/p\\u003e\\n\\u003cp\\u003eIn patient-based comparisons between radiopharmaceuticals, [\\u003csup\\u003e68\\u003c/sup\\u003eGa]-FAPI-04 PET/CT demonstrated significantly superior performance compared with both [\\u003csup\\u003e18\\u003c/sup\\u003eF]-FDG PET/CT (\\u0026chi;\\u003csup\\u003e2\\u003c/sup\\u003e = 4.17, \\u003cem\\u003ep=\\u003c/em\\u003e0.041) and [\\u003csup\\u003e18\\u003c/sup\\u003eF]-FDG PET/MR (\\u0026chi;\\u003csup\\u003e2\\u003c/sup\\u003e = 5.14, \\u003cem\\u003ep=\\u003c/em\\u003e0.023). Similarly, [\\u003csup\\u003e68\\u003c/sup\\u003eGa]-FAPI-04 PET/MR showed statistically significant advantages over [\\u003csup\\u003e18\\u003c/sup\\u003eF]-FDG PET/CT (\\u0026chi;\\u003csup\\u003e2\\u003c/sup\\u003e = 5.14, \\u003cem\\u003ep=\\u003c/em\\u003e0.023) and [\\u003csup\\u003e18\\u003c/sup\\u003eF]-FDG PET/MR (\\u0026chi;\\u003csup\\u003e2\\u003c/sup\\u003e = 6.13, \\u003cem\\u003ep=\\u003c/em\\u003e0.013). No significant differences were observed between PET/CT and PET/MR when using the same radiopharmaceutical, either for [\\u003csup\\u003e18\\u003c/sup\\u003eF]-FDG (\\u0026chi;\\u003csup\\u003e2\\u003c/sup\\u003e = 2.00, \\u003cem\\u003ep=\\u003c/em\\u003e0.157) or for [\\u003csup\\u003e68\\u003c/sup\\u003eGa]-FAPI-04 (\\u0026chi;\\u003csup\\u003e2\\u003c/sup\\u003e = 0, \\u003cem\\u003ep=\\u003c/em\\u003e1.000).\\u003c/p\\u003e\\n\\u003cp\\u003eIn lesion-based analysis, a total of 47 pathologically or follow-up\\u0026ndash;confirmed peritoneal lesions were identified in the 21 patients. Sensitivity was 42.9% (12/28) for [\\u003csup\\u003e18\\u003c/sup\\u003eF]-FDG PET/CT, 66.0% (31/47) for [\\u003csup\\u003e18\\u003c/sup\\u003eF]-FDG PET/MR, 91.5% (43/47) for [\\u003csup\\u003e68\\u003c/sup\\u003eGa]-FAPI-04 PET/CT, and 100.0% (47/47) for [\\u003csup\\u003e68\\u003c/sup\\u003eGa]-FAPI-04 PET/MR. Cross-radiopharmaceutical comparisons showed that both [\\u003csup\\u003e68\\u003c/sup\\u003eGa]-FAPI-04 PET/CT and PET/MR significantly outperformed [\\u003csup\\u003e18\\u003c/sup\\u003eF]-FDG PET/CT and PET/MR ( all \\u003cem\\u003ep\\u003c/em\\u003e\\u0026le; 0.001). No significant difference was observed between PET/CT and PET/MR for [\\u003csup\\u003e68\\u003c/sup\\u003eGa]-FAPI-04 (\\u0026chi;\\u003csup\\u003e2\\u003c/sup\\u003e = 0.25, \\u003cem\\u003ep=\\u003c/em\\u003e0.617). In contrast, [\\u003csup\\u003e18\\u003c/sup\\u003eF]-FDG PET/MR demonstrated significantly higher sensitivity than [\\u003csup\\u003e18\\u003c/sup\\u003eF]-FDG PET/CT (\\u0026chi;\\u003csup\\u003e2\\u003c/sup\\u003e = 4.57, \\u003cem\\u003ep=\\u003c/em\\u003e0.033).\\u003c/p\\u003e\\n\\u003cp\\u003eAs shown in Fig. 4, a 33-year-old female with signet ring cell gastric cancer (endoscopic biopsy-proven) exhibited prominent tracer accumulation in peritoneal lesions (white arrows) on [\\u003csup\\u003e68\\u003c/sup\\u003eGa]-FAPI-04 PET/CT and PET/MR, while [\\u003csup\\u003e18\\u003c/sup\\u003eF]-FDG PET/CT and PET/MR showed no such findings. Ultrasound-guided needle biopsy of these peritoneal lesions confirmed metastatic poorly differentiated carcinoma.\\u003c/p\\u003e\\n\\u003cp\\u003eWhen comparing radiopharmaceuticals on the same imaging platform, [\\u003csup\\u003e68\\u003c/sup\\u003eGa]-FAPI-04 PET/CT showed significantly higher SUV\\u003csub\\u003emax\\u003c/sub\\u003e than [\\u003csup\\u003e18\\u003c/sup\\u003eF]-FDG PET/CT (7.08 \\u0026plusmn; 3.61 vs. 2.71 \\u0026plusmn; 2.83, \\u003cem\\u003ep\\u003c/em\\u003e＜0.001), and [\\u003csup\\u003e68\\u003c/sup\\u003eGa]-FAPI-04 PET/MR likewise demonstrated higher SUV\\u003csub\\u003emax\\u003c/sub\\u003e than [\\u003csup\\u003e18\\u003c/sup\\u003eF]-FDG PET/MR (5.88 \\u0026plusmn; 3.27 vs. 1.94 \\u0026plusmn; 1.57, \\u003cem\\u003ep\\u003c/em\\u003e＜0.001). Correspondingly, TBR values were significantly higher for [\\u003csup\\u003e68\\u003c/sup\\u003eGa]-FAPI-04 than for [\\u003csup\\u003e18\\u003c/sup\\u003eF]-FDG on both PET/CT (8.25 \\u0026plusmn; 5.27 vs. 1.50 \\u0026plusmn; 1.55, \\u003cem\\u003ep\\u003c/em\\u003e＜0.001) and PET/MR (9.31 \\u0026plusmn; 6.28 vs. 1.28 \\u0026plusmn; 0.91, \\u003cem\\u003ep\\u003c/em\\u003e＜0.001).\\u003c/p\\u003e\\n\\u003cp\\u003eWhen comparing the same radiopharmaceutical across imaging platforms, [\\u003csup\\u003e68\\u003c/sup\\u003eGa]-FAPI-04 PET/CT demonstrated a higher SUV\\u003csub\\u003emax\\u003c/sub\\u003e than PET/MR (7.08 \\u0026plusmn; 3.61 vs. 5.88 \\u0026plusmn; 3.27, \\u003cem\\u003ep\\u003c/em\\u003e＜0.001), whereas PET/MR yielded a significantly higher TBR than PET/CT (9.31 \\u0026plusmn; 6.28 vs. 8.25 \\u0026plusmn; 5.27, \\u003cem\\u003ep=\\u003c/em\\u003e0.025). For [\\u003csup\\u003e18\\u003c/sup\\u003eF]-FDG, no significant differences in SUV\\u003csub\\u003emax\\u003c/sub\\u003e or TBR were observed between PET/CT and PET/MR (\\u003cem\\u003ep=\\u003c/em\\u003e0.353 and \\u003cem\\u003ep=\\u003c/em\\u003e0.086, respectively) (Fig. 2).\\u003c/p\\u003e\\n\\u003cp\\u003e\\u003cstrong\\u003eComparison of [\\u003csup\\u003e68\\u003c/sup\\u003eGa]-FAPI-04 and [\\u003csup\\u003e18\\u003c/sup\\u003eF]-FDG in the detection of other metastases\\u003c/strong\\u003e\\u003c/p\\u003e\\n\\u003cp\\u003eThe diagnostic performance of the four imaging modalities for the detection of ovarian and bone metastases is summarized in Table 2. Patient-based analysis was not performed because of the limited number of positive cases.\\u003c/p\\u003e\\n\\u003cp\\u003eIn lesion-based analyses, no statistically significant differences were observed among the four imaging modalities in the detection of either ovarian or bone metastases (all \\u003cem\\u003ep\\u003c/em\\u003e \\u0026gt;0.05).\\u003c/p\\u003e\\n\\u003cp\\u003eIn semi-quantitative analyses comparing radiopharmaceuticals on the same imaging platform, ovarian metastases demonstrated significantly higher SUV\\u003csub\\u003emax\\u003c/sub\\u003e and TBR with [\\u003csup\\u003e68\\u003c/sup\\u003eGa]-FAPI-04 than with [\\u003csup\\u003e18\\u003c/sup\\u003eF]-FDG on both PET/CT (SUV\\u003csub\\u003emax\\u003c/sub\\u003e: 4.41 \\u0026plusmn; 1.87 vs. 2.45 \\u0026plusmn; 0.75, \\u003cem\\u003ep=\\u003c/em\\u003e 0.043; TBR: 5.05 \\u0026plusmn; 2.85 vs. 1.36 \\u0026plusmn; 0.46, \\u003cem\\u003ep=\\u003c/em\\u003e 0.043) and PET/MR (SUV\\u003csub\\u003emax\\u003c/sub\\u003e: 3.03 \\u0026plusmn; 0.87 vs. 1.94 \\u0026plusmn; 0.91, \\u003cem\\u003ep=\\u003c/em\\u003e0.008; TBR: 6.58 \\u0026plusmn; 7.01 vs. 1.18 \\u0026plusmn; 0.20, \\u003cem\\u003ep=\\u003c/em\\u003e0.008). In contrast, for bone metastases, only the TBR measured with [\\u003csup\\u003e68\\u003c/sup\\u003eGa]-FAPI-04 PET/MR was significantly higher than that measured with [\\u003csup\\u003e18\\u003c/sup\\u003eF]-FDG PET/MR (13.50 \\u0026plusmn; 14.37 vs. 2.91 \\u0026plusmn; 1.37, \\u003cem\\u003ep=\\u003c/em\\u003e 0.038).\\u003c/p\\u003e\\n\\u003cp\\u003eWhen comparing the same radiopharmaceutical across different imaging platforms, [\\u003csup\\u003e68\\u003c/sup\\u003eGa]-FAPI-04 PET/CT demonstrated a significantly higher SUV\\u003csub\\u003emax\\u003c/sub\\u003e than PET/MR for ovarian metastases (21.81 vs. 15.12, \\u003cem\\u003ep=\\u003c/em\\u003e0.015), whereas no significant difference in TBR was observed (\\u003cem\\u003ep=\\u003c/em\\u003e0.515). For [\\u003csup\\u003e18\\u003c/sup\\u003eF]-FDG, no significant inter-platform differences were detected, likely reflecting the limited sample size. Similarly, statistical comparisons for bone metastases remained inconclusive because of the small number of cases (Fig. 2).\\u003c/p\\u003e\"},{\"header\":\"Discussion\",\"content\":\"\\u003cp\\u003eThis study represents the first systematic, head-to-head comparison of the diagnostic performance of [\\u003csup\\u003e68\\u003c/sup\\u003eGa]-FAPI-04 versus [\\u003csup\\u003e18\\u003c/sup\\u003eF]-FDG for gastric cancer staging across dual-modality PET/CT and PET/MR platforms. Our findings demonstrate that [\\u003csup\\u003e68\\u003c/sup\\u003eGa]-FAPI-04, a tumor-stroma-targeting tracer, outperforms [\\u003csup\\u003e18\\u003c/sup\\u003eF]-FDG in detecting primary gastric cancer lesions and metastases. Crucially, this study underscores the substantial influence of the imaging modality itself on diagnostic performance, highlighting the unique value of PET/MR for assessing peritoneal metastases and delivering superior lesion contrast.\\u003c/p\\u003e\\n\\u003cp\\u003eThe superior performance of [\\u003csup\\u003e68\\u003c/sup\\u003eGa]-FAPI-04 originates from its distinct mechanism of action. By targeting CAFs, which are characterized by high FAP expression within the tumor microenvironment, this tracer facilitates high-contrast visualization of gastric cancer lesions\\u0026nbsp;[10; 11]. We confirmed that, irrespective of the imaging platform (PET/CT or PET/MR), the SUV\\u003csub\\u003emax\\u003c/sub\\u003e and TBR of [\\u003csup\\u003e68\\u003c/sup\\u003eGa]-FAPI-04 in primary tumors, lymph nodes, and peritoneal metastases were significantly higher than those of [\\u003csup\\u003e18\\u003c/sup\\u003eF]-FDG. The false-negative lesions undetected by both tracers were pathologically confirmed as SRCC confined to the lamina propria; these were also missed by CT and MR, likely due to their minute size.\\u003c/p\\u003e\\n\\u003cp\\u003ePrevious studies have reported lower [\\u003csup\\u003e18\\u003c/sup\\u003eF]-FDG uptake in SRCC and mucinous adenocarcinoma compared to conventional adenocarcinoma, a phenomenon associated with reduced expression of glucose transporter 1 (GLUT-1) [12].\\u0026nbsp;Our subgroup analysis revealed significantly higher [\\u003csup\\u003e68\\u003c/sup\\u003eGa]-FAPI-04 uptake than [\\u003csup\\u003e18\\u003c/sup\\u003eF]-FDG in 15 patients with SRCC, a finding consistent with prior research\\u0026nbsp;[13; 14].\\u0026nbsp;However, in the non-SRCC group, [\\u003csup\\u003e68\\u003c/sup\\u003eGa]-FAPI-04 uptake (SUV\\u003csub\\u003emax\\u003c/sub\\u003e and TBR) was also significantly higher than that of [\\u003csup\\u003e18\\u003c/sup\\u003eF]-FDG. This result differs from the findings reported by Rong et al.\\u0026nbsp;[8].\\u0026nbsp;This discrepancy may be attributed to the fact that CAFs are a major component of the tumor stroma in most epithelial-derived tumors, including all histological subtypes of gastric cancer, and typically exhibit high FAP expression\\u0026nbsp;[15].\\u0026nbsp;Non-SRCC tumors showed higher [\\u003csup\\u003e18\\u003c/sup\\u003eF]-FDG uptake (including SUV\\u003csub\\u003emax\\u003c/sub\\u003e and TBR) than SRCC (all \\u003cem\\u003ep\\u003c/em\\u003e＜0.05), reflecting higher tumor cell metabolic activity. This confirms the well-recognized clinical challenge that SRCC, as a hypometabolic subtype, often leads to insufficient sensitivity on FDG PET\\u0026nbsp;[16].\\u0026nbsp;In contrast, [\\u003csup\\u003e68\\u003c/sup\\u003eGa]-FAPI-04 showed no significant difference in uptake between the two subgroups (all \\u003cem\\u003ep\\u003c/em\\u003e \\u0026gt;0.05).\\u003c/p\\u003e\\n\\u003cp\\u003eThis advantage is particularly critical for detecting peritoneal metastases, with [\\u003csup\\u003e68\\u003c/sup\\u003eGa]-FAPI-04 PET/MR achieving 100% sensitivity and specificity. We found that [\\u003csup\\u003e68\\u003c/sup\\u003eGa]-FAPI-04 outperformed [\\u003csup\\u003e18\\u003c/sup\\u003eF]-FDG in detecting peritoneal metastases providing more distinct tracer uptake (Fig.4), which aligns with previous reports\\u0026nbsp;[9; 17-19]. This effectively overcomes the limitations of [\\u003csup\\u003e18\\u003c/sup\\u003eF]-FDG associated with tumor metabolic heterogeneity and physiological abdominal uptake\\u0026nbsp;[20-22].\\u0026nbsp;Lymph node staging is crucial for gastric cancer management and prognosis, yet the value of [\\u003csup\\u003e18\\u003c/sup\\u003eF]-FDG PET/CT in this context remains controversial. Our study, which used postoperative pathology as the gold standard in 14 surgically treated patients, found higher [\\u003csup\\u003e68\\u003c/sup\\u003eGa]-FAPI-04 uptake in metastatic lymph nodes compared to [\\u003csup\\u003e18\\u003c/sup\\u003eF]-FDG (Fig.3), consistent with previous studies\\u0026nbsp;[8; 20].\\u0026nbsp;However, the diagnostic sensitivities across the four imaging modalities were relatively low (approximately 20\\u0026ndash;27%), consistent with prior reports\\u0026nbsp;[9].\\u0026nbsp;The primary reason is that most dissected lymph nodes were small in volume, making them difficult to detect even with the high soft-tissue resolution of MR\\u0026nbsp;[23; 24].\\u003c/p\\u003e\\n\\u003cp\\u003eRegarding imaging modalities, PET/CT and PET/MR exhibited distinct utilities and a complementary relationship. A key finding was that for the same tracer, SUV\\u003csub\\u003emax\\u003c/sub\\u003e measured by the uEXPLORER total-body PET/CT was consistently higher than that obtained from PET/MR. This primarily arises from inherent differences in attenuation correction principles and reconstruction algorithms, combined with the uEXPLORER scanner\\u0026apos;s ultra-high system sensitivity and extended axial field of view, which enable extremely low noise and precise quantitative analysis [25-27]. However, for lesion detection and contrast, PET/MR leveraged its superior soft-tissue resolution and different attenuation correction approaches to yield a superior TBR in most instances [9; 28; 29]. This advantage synergized with the highly specific FAP tracer, rendering PET/MR more adept at identifying subtle peritoneal implants, miliary nodules, and accurately assessing the local invasion extent of primary tumors [30].\\u003c/p\\u003e\\n\\u003cp\\u003eThe innovations of this study include the first systematic assessment of [\\u003csup\\u003e68\\u003c/sup\\u003eGa]-FAPI-04 versus [\\u003csup\\u003e18\\u003c/sup\\u003eF]-FDG for gastric cancer staging across dual PET/CT and PET/MR platforms, and the pioneering application of the state-of-the-art uEXPLORER PET/CT system, whose ultra-high sensitivity and total-body coverage offered unique advantages for precise quantitative analysis.\\u003c/p\\u003e\\n\\u003cp\\u003eSeveral limitations must be acknowledged. First, this was a single-center, retrospective study with a relatively small sample size in specific metastatic subgroups. Second, the high proportion of SRCC in our cohort (57.1%), while underscoring the diagnostic advantage of [\\u003csup\\u003e68\\u003c/sup\\u003eGa]-FAPI-04 for hypometabolic tumors, may limit the generalizability of findings to populations with different pathological distributions. Third, most patients lacked surgical or histopathological confirmation of metastases, with validation primarily based on clinical follow-up and other imaging modalities. Finally, the sample sizes for bone and ovarian metastases were limited; these results are therefore exploratory, and statistically robust comparisons necessitate validation in larger cohorts. Future prospective, multi-center studies are warranted to validate these findings.\\u003c/p\\u003e\"},{\"header\":\"Conclusion\",\"content\":\"\\u003cp\\u003eThe combination of the tumor-stroma-targeting tracer [\\u003csup\\u003e68\\u003c/sup\\u003eGa]-FAPI-04 and PET/MR represents one of the most promising imaging strategies for gastric cancer staging, effectively leveraging the superior soft-tissue resolution of MRI. This approach is particularly valuable for detecting peritoneal metastases and evaluating [\\u003csup\\u003e18\\u003c/sup\\u003eF]-FDG-insensitive tumor subtypes. The demonstrated advantages of [\\u003csup\\u003e68\\u003c/sup\\u003eGa]-FAPI-04 over [\\u003csup\\u003e18\\u003c/sup\\u003eF]-FDG, coupled with the added diagnostic value of PET/MR relative to PET/CT in key clinical scenarios, provide compelling evidence for the utility of this strategy in refining gastric cancer staging and optimizing personalized treatment decisions.\\u003c/p\\u003e\"},{\"header\":\"References\",\"content\":\"\\u003col\\u003e\\n\\u003cli\\u003eBray F, Laversanne M, Sung H et al (2024) Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 74:229-263\\u003c/li\\u003e\\n\\u003cli\\u003eSundar R, Nakayama I, Markar SR et al (2025) Gastric cancer. Lancet 405:2087-2102\\u003c/li\\u003e\\n\\u003cli\\u003eGiandola T, Maino C, Marrapodi G et al (2023) Imaging in Gastric Cancer: Current Practice and Future Perspectives. Diagnostics (Basel) 13\\u003c/li\\u003e\\n\\u003cli\\u003eAjani JA, D\\u0026apos;Amico TA, Bentrem DJ et al (2022) Gastric Cancer, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw 20:167-192\\u003c/li\\u003e\\n\\u003cli\\u003eFilik M, Kir KM, Aksel B et al (2015) The Role of 18F-FDG PET/CT in the Primary Staging of Gastric Cancer. Mol Imaging Radionucl Ther 24:15-20\\u003c/li\\u003e\\n\\u003cli\\u003eSong Z, Wu Y, Yang J, Yang D, Fang X (2017) Progress in the treatment of advanced gastric cancer. Tumour Biol 39:1010428317714626\\u003c/li\\u003e\\n\\u003cli\\u003eWang Y, Luo W, Li Y (2023) [(68)Ga]Ga-FAPI-04 PET MRI/CT in the evaluation of gastric carcinomas compared with [(18)F]-FDG PET MRI/CT: a meta-analysis. Eur J Med Res 28:34\\u003c/li\\u003e\\n\\u003cli\\u003eLin R, Lin Z, Chen Z et al (2022) [(68)Ga]Ga-DOTA-FAPI-04 PET/CT in the evaluation of gastric cancer: comparison with [(18)F]FDG PET/CT. Eur J Nucl Med Mol Imaging 49:2960-2971\\u003c/li\\u003e\\n\\u003cli\\u003eQin C, Shao F, Gai Y et al (2022) (68)Ga-DOTA-FAPI-04 PET/MR in the Evaluation of Gastric Carcinomas: Comparison with (18)F-FDG PET/CT. J Nucl Med 63:81-88\\u003c/li\\u003e\\n\\u003cli\\u003eFu Y, Qin C, Li M et al (2025) Comparative Evaluation of 68Ga-FAPI-04 PET for Initial N and M Staging in Gastric Cancer: A Study Against Histopathology and Contrast-Enhanced CT. Clin Nucl Med 50:394-403\\u003c/li\\u003e\\n\\u003cli\\u003eJiang D, Chen X, You Z et al (2022) Comparison of [(68) Ga]Ga-FAPI-04 and [(18)F]-FDG for the detection of primary and metastatic lesions in patients with gastric cancer: a bicentric retrospective study. Eur J Nucl Med Mol Imaging 49:732-742\\u003c/li\\u003e\\n\\u003cli\\u003eKoppula BR, Fine GC, Salem AE et al (2022) PET-CT in Clinical Adult Oncology: III. Gastrointestinal Malignancies. Cancers (Basel) 14\\u003c/li\\u003e\\n\\u003cli\\u003eWang T, Huang G, Zhao H et al (2024) [(68)Ga]Ga-FAPI-04 PET/MR imaging strategy in management of Krukenberg tumors (KTs) from gastric signet-ring-cell carcinoma: to overcome limitation of [(68)Ga]Ga-FAPI-04 PET imaging in KTs. Eur J Nucl Med Mol Imaging 51:3440-3449\\u003c/li\\u003e\\n\\u003cli\\u003eChen H, Pang Y, Li J et al (2023) Comparison of [(68)Ga]Ga-FAPI and [(18)F]FDG uptake in patients with gastric signet-ring-cell carcinoma: a multicenter retrospective study. Eur Radiol 33:1329-1341\\u003c/li\\u003e\\n\\u003cli\\u003eOya Y, Hayakawa Y, Koike K (2020) Tumor microenvironment in gastric cancers. Cancer Sci 111:2696-2707\\u003c/li\\u003e\\n\\u003cli\\u003eStahl A, Ott K, Weber WA et al (2003) FDG PET imaging of locally advanced gastric carcinomas: correlation with endoscopic and histopathological findings. Eur J Nucl Med Mol Imaging 30:288-295\\u003c/li\\u003e\\n\\u003cli\\u003eZhao L, Pang Y, Luo Z et al (2021) Role of [(68)Ga]Ga-DOTA-FAPI-04 PET/CT in the evaluation of peritoneal carcinomatosis and comparison with [(18)F]-FDG PET/CT. Eur J Nucl Med Mol Imaging 48:1944-1955\\u003c/li\\u003e\\n\\u003cli\\u003eKuten J, Levine C, Shamni O et al (2022) Head-to-head comparison of [(68)Ga]Ga-FAPI-04 and [(18)F]-FDG PET/CT in evaluating the extent of disease in gastric adenocarcinoma. Eur J Nucl Med Mol Imaging 49:743-750\\u003c/li\\u003e\\n\\u003cli\\u003eLi C, Tian Y, Chen J et al (2023) Usefulness of [(68)Ga]FAPI-04 and [(18)F]FDG PET/CT for the detection of primary tumour and metastatic lesions in gastrointestinal carcinoma: a comparative study. Eur Radiol 33:2779-2791\\u003c/li\\u003e\\n\\u003cli\\u003ePang Y, Zhao L, Luo Z et al (2021) Comparison of (68)Ga-FAPI and (18)F-FDG Uptake in Gastric, Duodenal, and Colorectal Cancers. Radiology 298:393-402\\u003c/li\\u003e\\n\\u003cli\\u003eYang T, Ma L, Hou H, Gao F, Tao W (2021) FAPI PET/CT in the Diagnosis of Abdominal and Pelvic Tumors. Front Oncol 11:797960\\u003c/li\\u003e\\n\\u003cli\\u003eQin C, Song Y, Gai Y et al (2022) Gallium-68-labeled fibroblast activation protein inhibitor PET in gastrointestinal cancer: insights into diagnosis and management. Eur J Nucl Med Mol Imaging 49:4228-4240\\u003c/li\\u003e\\n\\u003cli\\u003eLiu B, Ramalho M, AlObaidy M et al (2014) Gastrointestinal imaging-practical magnetic resonance imaging approach. World J Radiol 6:544-566\\u003c/li\\u003e\\n\\u003cli\\u003eKwee RM, Kwee TC (2009) Imaging in assessing lymph node status in gastric cancer. Gastric Cancer 12:6-22\\u003c/li\\u003e\\n\\u003cli\\u003eZhang X, Xie Z, Berg E et al (2020) Total-Body Dynamic Reconstruction and Parametric Imaging on the uEXPLORER. J Nucl Med 61:285-291\\u003c/li\\u003e\\n\\u003cli\\u003eWu Y, Feng T, Zhao Y et al (2022) Whole-Body Parametric Imaging of (18)F-FDG PET Using uEXPLORER with Reduced Scanning Time. J Nucl Med 63:622-628\\u003c/li\\u003e\\n\\u003cli\\u003eLiu G, Mao W, Yu H, Hu Y, Gu J, Shi H (2023) One-stop [(18)F]FDG and [(68)Ga]Ga-DOTA-FAPI-04 total-body PET/CT examination with dual-low activity: a feasibility study. Eur J Nucl Med Mol Imaging 50:2271-2281\\u003c/li\\u003e\\n\\u003cli\\u003eDrzezga A, Souvatzoglou M, Eiber M et al (2012) First clinical experience with integrated whole-body PET/MR: comparison to PET/CT in patients with oncologic diagnoses. J Nucl Med 53:845-855\\u003c/li\\u003e\\n\\u003cli\\u003eF\\u0026uuml;rst S, Grimm R, Hong I et al (2015) Motion correction strategies for integrated PET/MR. J Nucl Med 56:261-269\\u003c/li\\u003e\\n\\u003cli\\u003eZheng W, Liu L, Feng Y, Wang L, Chen Y (2023) Comparison of 68 Ga-FAPI-04 and fluorine-18-fluorodeoxyglucose PET/computed tomography in the detection of ovarian malignancies. Nucl Med Commun 44:194-203\\u003c/li\\u003e\\n\\u003c/ol\\u003e\"},{\"header\":\"Tables\",\"content\":\"\\u003cp\\u003e\\u003cstrong\\u003eTable 1\\u0026nbsp;\\u003c/strong\\u003ePatient characteristics\\u003c/p\\u003e\\n\\u003ctable border=\\\"1\\\" cellspacing=\\\"0\\\" cellpadding=\\\"0\\\"\\u003e\\n \\u003ctbody\\u003e\\n \\u003ctr\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 277px;\\\"\\u003e\\n \\u003cp\\u003eCharacteristics\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 139px;\\\"\\u003e\\n \\u003cp\\u003eN\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003c/tr\\u003e\\n \\u003ctr\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 277px;\\\"\\u003e\\n \\u003cp\\u003ePatient No.\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 139px;\\\"\\u003e\\n \\u003cp\\u003e35\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003c/tr\\u003e\\n \\u003ctr\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 277px;\\\"\\u003e\\n \\u003cp\\u003eAge (years)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 139px;\\\"\\u003e\\n \\u003cp\\u003e\\u0026nbsp;\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003c/tr\\u003e\\n \\u003ctr\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 277px;\\\"\\u003e\\n \\u003cp\\u003eMedian (range)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 139px;\\\"\\u003e\\n \\u003cp\\u003e52.1 \\u0026plusmn; 13.5 (26\\u0026ndash;76)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003c/tr\\u003e\\n \\u003ctr\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 277px;\\\"\\u003e\\n \\u003cp\\u003eSex\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 139px;\\\"\\u003e\\n \\u003cp\\u003e\\u0026nbsp;\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003c/tr\\u003e\\n \\u003ctr\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 277px;\\\"\\u003e\\n \\u003cp\\u003eMale\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 139px;\\\"\\u003e\\n \\u003cp\\u003e10 (28.6%)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003c/tr\\u003e\\n \\u003ctr\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 277px;\\\"\\u003e\\n \\u003cp\\u003eFemale\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 139px;\\\"\\u003e\\n \\u003cp\\u003e25 (71.4%)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003c/tr\\u003e\\n \\u003ctr\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 277px;\\\"\\u003e\\n \\u003cp\\u003eHistopathology\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 139px;\\\"\\u003e\\n \\u003cp\\u003e\\u0026nbsp;\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003c/tr\\u003e\\n \\u003ctr\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 277px;\\\"\\u003e\\n \\u003cp\\u003eSRCC\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 139px;\\\"\\u003e\\n \\u003cp\\u003e20 (57.1%)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003c/tr\\u003e\\n \\u003ctr\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 277px;\\\"\\u003e\\n \\u003cp\\u003eNon-SRCC\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 139px;\\\"\\u003e\\n \\u003cp\\u003e15 (42.9%)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003c/tr\\u003e\\n \\u003ctr\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 277px;\\\"\\u003e\\n \\u003cp\\u003eGrade\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 139px;\\\"\\u003e\\n \\u003cp\\u003e\\u0026nbsp;\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003c/tr\\u003e\\n \\u003ctr\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 277px;\\\"\\u003e\\n \\u003cp\\u003eModerately/moderately to poorly\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 139px;\\\"\\u003e\\n \\u003cp\\u003e8 (22.9%)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003c/tr\\u003e\\n \\u003ctr\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 277px;\\\"\\u003e\\n \\u003cp\\u003ePoorly\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 139px;\\\"\\u003e\\n \\u003cp\\u003e27 (77.1%)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003c/tr\\u003e\\n \\u003ctr\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 277px;\\\"\\u003e\\n \\u003cp\\u003eT stage\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 139px;\\\"\\u003e\\n \\u003cp\\u003e\\u0026nbsp;\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003c/tr\\u003e\\n \\u003ctr\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 277px;\\\"\\u003e\\n \\u003cp\\u003eT1-2\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 139px;\\\"\\u003e\\n \\u003cp\\u003e6 (17.1%)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003c/tr\\u003e\\n \\u003ctr\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 277px;\\\"\\u003e\\n \\u003cp\\u003eT3-4\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 139px;\\\"\\u003e\\n \\u003cp\\u003e29 (82.9%)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003c/tr\\u003e\\n \\u003ctr\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 277px;\\\"\\u003e\\n \\u003cp\\u003eN stage\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 139px;\\\"\\u003e\\n \\u003cp\\u003e\\u0026nbsp;\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003c/tr\\u003e\\n \\u003ctr\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 277px;\\\"\\u003e\\n \\u003cp\\u003eN0\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 139px;\\\"\\u003e\\n \\u003cp\\u003e14 (40%)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003c/tr\\u003e\\n \\u003ctr\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 277px;\\\"\\u003e\\n \\u003cp\\u003eN+\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 139px;\\\"\\u003e\\n \\u003cp\\u003e21 (60%)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003c/tr\\u003e\\n \\u003ctr\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 277px;\\\"\\u003e\\n \\u003cp\\u003eM stage\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 139px;\\\"\\u003e\\n \\u003cp\\u003e\\u0026nbsp;\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003c/tr\\u003e\\n \\u003ctr\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 277px;\\\"\\u003e\\n \\u003cp\\u003eM0\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 139px;\\\"\\u003e\\n \\u003cp\\u003e10 (28.6%)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003c/tr\\u003e\\n \\u003ctr\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 277px;\\\"\\u003e\\n \\u003cp\\u003eM1\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 139px;\\\"\\u003e\\n \\u003cp\\u003e25 (71.4%)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003c/tr\\u003e\\n \\u003ctr\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 277px;\\\"\\u003e\\n \\u003cp\\u003eClinical stage\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 139px;\\\"\\u003e\\n \\u003cp\\u003e\\u0026nbsp;\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003c/tr\\u003e\\n \\u003ctr\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 277px;\\\"\\u003e\\n \\u003cp\\u003eⅠ\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 139px;\\\"\\u003e\\n \\u003cp\\u003e5\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003c/tr\\u003e\\n \\u003ctr\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 277px;\\\"\\u003e\\n \\u003cp\\u003eⅡ\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 139px;\\\"\\u003e\\n \\u003cp\\u003e1\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003c/tr\\u003e\\n \\u003ctr\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 277px;\\\"\\u003e\\n \\u003cp\\u003eⅢ\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 139px;\\\"\\u003e\\n \\u003cp\\u003e3\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003c/tr\\u003e\\n \\u003ctr\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 277px;\\\"\\u003e\\n \\u003cp\\u003eⅣ\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 139px;\\\"\\u003e\\n \\u003cp\\u003e26\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003c/tr\\u003e\\n \\u003ctr\\u003e\\n \\u003ctd colspan=\\\"2\\\" valign=\\\"top\\\" style=\\\"width: 416px;\\\"\\u003e\\n \\u003cp\\u003eAbbreviations: No., number; SRCC, signet-ring cell carcinoma.\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003c/tr\\u003e\\n \\u003c/tbody\\u003e\\n\\u003c/table\\u003e\\n\\u003cp\\u003e\\u0026nbsp;\\u003c/p\\u003e\\n\\u003cp\\u003e\\u003cstrong\\u003eTable 2\\u0026nbsp;\\u003c/strong\\u003eDiagnostic performance of [\\u003csup\\u003e18\\u003c/sup\\u003eF]-FDG and [\\u003csup\\u003e68\\u003c/sup\\u003eGa]-FAPI-04 in PET/CT and PET/MR\\u003c/p\\u003e\\n\\u003ctable border=\\\"1\\\" cellspacing=\\\"0\\\" cellpadding=\\\"0\\\" width=\\\"100%\\\"\\u003e\\n \\u003ctbody\\u003e\\n \\u003ctr\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 17px;\\\"\\u003e\\n \\u003cp\\u003e\\u0026nbsp;\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 16px;\\\"\\u003e\\n \\u003cp\\u003eSensitivity % (n/n)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 16px;\\\"\\u003e\\n \\u003cp\\u003eSpecificity % (n/n)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 15px;\\\"\\u003e\\n \\u003cp\\u003eAccuracy % (n/n)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 16px;\\\"\\u003e\\n \\u003cp\\u003ePositive predictive\\u0026nbsp;\\u003c/p\\u003e\\n \\u003cp\\u003evalue % (n/n)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 16px;\\\"\\u003e\\n \\u003cp\\u003eNegative predictive\\u0026nbsp;\\u003c/p\\u003e\\n \\u003cp\\u003evalue % (n/n)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003c/tr\\u003e\\n \\u003ctr\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 17px;\\\"\\u003e\\n \\u003cp\\u003e[\\u003csup\\u003e18\\u003c/sup\\u003eF]-FDG PET/CT\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 16px;\\\"\\u003e\\n \\u003cp\\u003e\\u0026nbsp;\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 16px;\\\"\\u003e\\n \\u003cp\\u003e\\u0026nbsp;\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 15px;\\\"\\u003e\\n \\u003cp\\u003e\\u0026nbsp;\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 16px;\\\"\\u003e\\n \\u003cp\\u003e\\u0026nbsp;\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 16px;\\\"\\u003e\\n \\u003cp\\u003e\\u0026nbsp;\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003c/tr\\u003e\\n \\u003ctr\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 17px;\\\"\\u003e\\n \\u003cp\\u003ePrimary tumor\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 16px;\\\"\\u003e\\n \\u003cp\\u003e95.5 (21/22)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 16px;\\\"\\u003e\\n \\u003cp\\u003eNA\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 15px;\\\"\\u003e\\n \\u003cp\\u003e95.5 (21/22)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 16px;\\\"\\u003e\\n \\u003cp\\u003e100 (21/21)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 16px;\\\"\\u003e\\n \\u003cp\\u003eNA\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003c/tr\\u003e\\n \\u003ctr\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 17px;\\\"\\u003e\\n \\u003cp\\u003eLymph node\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 16px;\\\"\\u003e\\n \\u003cp\\u003e69.2 (9/13)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 16px;\\\"\\u003e\\n \\u003cp\\u003e66.7 (6/9)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 15px;\\\"\\u003e\\n \\u003cp\\u003e68.1 (15/22)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 16px;\\\"\\u003e\\n \\u003cp\\u003e75 (9/12)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 16px;\\\"\\u003e\\n \\u003cp\\u003e60 (6/10)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003c/tr\\u003e\\n \\u003ctr\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 17px;\\\"\\u003e\\n \\u003cp\\u003ePeritoneal\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 16px;\\\"\\u003e\\n \\u003cp\\u003e41.7 (5/12)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 16px;\\\"\\u003e\\n \\u003cp\\u003e100 (10/10)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 15px;\\\"\\u003e\\n \\u003cp\\u003e68.2 (15/22)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 16px;\\\"\\u003e\\n \\u003cp\\u003e100 (5/5)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 16px;\\\"\\u003e\\n \\u003cp\\u003e58.8 (10/17)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003c/tr\\u003e\\n \\u003ctr\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 17px;\\\"\\u003e\\n \\u003cp\\u003eBone\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 16px;\\\"\\u003e\\n \\u003cp\\u003e100 (1/1)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 16px;\\\"\\u003e\\n \\u003cp\\u003e100 (21/21)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 15px;\\\"\\u003e\\n \\u003cp\\u003e100 (22/22)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 16px;\\\"\\u003e\\n \\u003cp\\u003e100 (1/1)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 16px;\\\"\\u003e\\n \\u003cp\\u003e100 (21/21)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003c/tr\\u003e\\n \\u003ctr\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 17px;\\\"\\u003e\\n \\u003cp\\u003eOvary\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 16px;\\\"\\u003e\\n \\u003cp\\u003e66.7 (2/3)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 16px;\\\"\\u003e\\n \\u003cp\\u003e92.3 (12/13)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 15px;\\\"\\u003e\\n \\u003cp\\u003e87.5 (14/16)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 16px;\\\"\\u003e\\n \\u003cp\\u003e66.7 (2/3)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 16px;\\\"\\u003e\\n \\u003cp\\u003e92.3 (12/13)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003c/tr\\u003e\\n \\u003ctr\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 17px;\\\"\\u003e\\n \\u003cp\\u003e[\\u003csup\\u003e18\\u003c/sup\\u003eF]-FDG PET/MR\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 16px;\\\"\\u003e\\n \\u003cp\\u003e\\u0026nbsp;\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 16px;\\\"\\u003e\\n \\u003cp\\u003e\\u0026nbsp;\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 15px;\\\"\\u003e\\n \\u003cp\\u003e\\u0026nbsp;\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 16px;\\\"\\u003e\\n \\u003cp\\u003e\\u0026nbsp;\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 16px;\\\"\\u003e\\n \\u003cp\\u003e\\u0026nbsp;\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003c/tr\\u003e\\n \\u003ctr\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 17px;\\\"\\u003e\\n \\u003cp\\u003ePrimary tumor\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 16px;\\\"\\u003e\\n \\u003cp\\u003e97.1 (33/34)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 16px;\\\"\\u003e\\n \\u003cp\\u003eNA\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 15px;\\\"\\u003e\\n \\u003cp\\u003e97.1 (33/34)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 16px;\\\"\\u003e\\n \\u003cp\\u003e100 (34/34)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 16px;\\\"\\u003e\\n \\u003cp\\u003eNA\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003c/tr\\u003e\\n \\u003ctr\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 17px;\\\"\\u003e\\n \\u003cp\\u003eLymph node\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 16px;\\\"\\u003e\\n \\u003cp\\u003e75 (15/20)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 16px;\\\"\\u003e\\n \\u003cp\\u003e85.7 (12/14)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 15px;\\\"\\u003e\\n \\u003cp\\u003e79.4 (27/34)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 16px;\\\"\\u003e\\n \\u003cp\\u003e88.2 (15/17)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 16px;\\\"\\u003e\\n \\u003cp\\u003e70.6 (12/17)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003c/tr\\u003e\\n \\u003ctr\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 17px;\\\"\\u003e\\n \\u003cp\\u003ePeritoneal\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 16px;\\\"\\u003e\\n \\u003cp\\u003e66.7 (14/21)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 16px;\\\"\\u003e\\n \\u003cp\\u003e100 (13/13)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 15px;\\\"\\u003e\\n \\u003cp\\u003e79.4 (27/34)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 16px;\\\"\\u003e\\n \\u003cp\\u003e100 (14/14)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 16px;\\\"\\u003e\\n \\u003cp\\u003e65 (13/20)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003c/tr\\u003e\\n \\u003ctr\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 17px;\\\"\\u003e\\n \\u003cp\\u003eBone\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 16px;\\\"\\u003e\\n \\u003cp\\u003e100 (3/3)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 16px;\\\"\\u003e\\n \\u003cp\\u003e100 (31/31)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 15px;\\\"\\u003e\\n \\u003cp\\u003e100 (34/34)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 16px;\\\"\\u003e\\n \\u003cp\\u003e100 (3/3)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 16px;\\\"\\u003e\\n \\u003cp\\u003e100 (31/31)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003c/tr\\u003e\\n \\u003ctr\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 17px;\\\"\\u003e\\n \\u003cp\\u003eOvary\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 16px;\\\"\\u003e\\n \\u003cp\\u003e100 (5/5)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 16px;\\\"\\u003e\\n \\u003cp\\u003e94.7 (18/19)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 15px;\\\"\\u003e\\n \\u003cp\\u003e95.8 (23/24)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 16px;\\\"\\u003e\\n \\u003cp\\u003e83.3 (5/6)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 16px;\\\"\\u003e\\n \\u003cp\\u003e100 (18/18)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003c/tr\\u003e\\n \\u003ctr\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 17px;\\\"\\u003e\\n \\u003cp\\u003e[\\u003csup\\u003e68\\u003c/sup\\u003eGa]-FAPI PET/CT\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 16px;\\\"\\u003e\\n \\u003cp\\u003e\\u0026nbsp;\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 16px;\\\"\\u003e\\n \\u003cp\\u003e\\u0026nbsp;\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 15px;\\\"\\u003e\\n \\u003cp\\u003e\\u0026nbsp;\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 16px;\\\"\\u003e\\n \\u003cp\\u003e\\u0026nbsp;\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 16px;\\\"\\u003e\\n \\u003cp\\u003e\\u0026nbsp;\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003c/tr\\u003e\\n \\u003ctr\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 17px;\\\"\\u003e\\n \\u003cp\\u003ePrimary tumor\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 16px;\\\"\\u003e\\n \\u003cp\\u003e97.1 (34/35)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 16px;\\\"\\u003e\\n \\u003cp\\u003eNA\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 15px;\\\"\\u003e\\n \\u003cp\\u003e97.1 (34/35)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 16px;\\\"\\u003e\\n \\u003cp\\u003e100 (35/35)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 16px;\\\"\\u003e\\n \\u003cp\\u003eNA\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003c/tr\\u003e\\n \\u003ctr\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 17px;\\\"\\u003e\\n \\u003cp\\u003eLymph node\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 16px;\\\"\\u003e\\n \\u003cp\\u003e85.7 (18/21)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 16px;\\\"\\u003e\\n \\u003cp\\u003e100 (14/14)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 15px;\\\"\\u003e\\n \\u003cp\\u003e91.4 (32/35)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 16px;\\\"\\u003e\\n \\u003cp\\u003e100 (18/18)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 16px;\\\"\\u003e\\n \\u003cp\\u003e82.3 (14/17)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003c/tr\\u003e\\n \\u003ctr\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 17px;\\\"\\u003e\\n \\u003cp\\u003ePeritoneal\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 16px;\\\"\\u003e\\n \\u003cp\\u003e95.2 (20/21)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 16px;\\\"\\u003e\\n \\u003cp\\u003e100 (14/14)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 15px;\\\"\\u003e\\n \\u003cp\\u003e97.1 (34/35)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 16px;\\\"\\u003e\\n \\u003cp\\u003e100 (20/20)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 16px;\\\"\\u003e\\n \\u003cp\\u003e93.3 (14/15)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003c/tr\\u003e\\n \\u003ctr\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 17px;\\\"\\u003e\\n \\u003cp\\u003eBone\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 16px;\\\"\\u003e\\n \\u003cp\\u003e100 (3/3)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 16px;\\\"\\u003e\\n \\u003cp\\u003e100 (32/32)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 15px;\\\"\\u003e\\n \\u003cp\\u003e100 (35/35)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 16px;\\\"\\u003e\\n \\u003cp\\u003e100 (3/3)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 16px;\\\"\\u003e\\n \\u003cp\\u003e100 (32/32)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003c/tr\\u003e\\n \\u003ctr\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 17px;\\\"\\u003e\\n \\u003cp\\u003eOvary\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 16px;\\\"\\u003e\\n \\u003cp\\u003e100 (5/5)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 16px;\\\"\\u003e\\n \\u003cp\\u003e100 (20/20)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 15px;\\\"\\u003e\\n \\u003cp\\u003e100 (25/25)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 16px;\\\"\\u003e\\n \\u003cp\\u003e100 (5/5)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 16px;\\\"\\u003e\\n \\u003cp\\u003e100 (20/20)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003c/tr\\u003e\\n \\u003ctr\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 17px;\\\"\\u003e\\n \\u003cp\\u003e[\\u003csup\\u003e68\\u003c/sup\\u003eGa]-FAPI PET/MR\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 16px;\\\"\\u003e\\n \\u003cp\\u003e\\u0026nbsp;\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 16px;\\\"\\u003e\\n \\u003cp\\u003e\\u0026nbsp;\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 15px;\\\"\\u003e\\n \\u003cp\\u003e\\u0026nbsp;\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 16px;\\\"\\u003e\\n \\u003cp\\u003e\\u0026nbsp;\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 16px;\\\"\\u003e\\n \\u003cp\\u003e\\u0026nbsp;\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003c/tr\\u003e\\n \\u003ctr\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 17px;\\\"\\u003e\\n \\u003cp\\u003ePrimary tumor\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 16px;\\\"\\u003e\\n \\u003cp\\u003e97.1 (34/35)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 16px;\\\"\\u003e\\n \\u003cp\\u003eNA\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 15px;\\\"\\u003e\\n \\u003cp\\u003e97.1 (34/35)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 16px;\\\"\\u003e\\n \\u003cp\\u003e100 (35/35)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 16px;\\\"\\u003e\\n \\u003cp\\u003eNA\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003c/tr\\u003e\\n \\u003ctr\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 17px;\\\"\\u003e\\n \\u003cp\\u003eLymph node\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 16px;\\\"\\u003e\\n \\u003cp\\u003e85.7 (18/21)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 16px;\\\"\\u003e\\n \\u003cp\\u003e100 (14/14)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 15px;\\\"\\u003e\\n \\u003cp\\u003e91.4 (32/35)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 16px;\\\"\\u003e\\n \\u003cp\\u003e100 (18/18)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 16px;\\\"\\u003e\\n \\u003cp\\u003e82.3 (14/17)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003c/tr\\u003e\\n \\u003ctr\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 17px;\\\"\\u003e\\n \\u003cp\\u003ePeritoneal\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 16px;\\\"\\u003e\\n \\u003cp\\u003e100 (21/21)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 16px;\\\"\\u003e\\n \\u003cp\\u003e100 (14/14)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 15px;\\\"\\u003e\\n \\u003cp\\u003e100 (35/35)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 16px;\\\"\\u003e\\n \\u003cp\\u003e100 (21/21)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 16px;\\\"\\u003e\\n \\u003cp\\u003e100 (14/14)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003c/tr\\u003e\\n \\u003ctr\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 17px;\\\"\\u003e\\n \\u003cp\\u003eBone\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 16px;\\\"\\u003e\\n \\u003cp\\u003e100 (3/3)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 16px;\\\"\\u003e\\n \\u003cp\\u003e100 (32/32)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 15px;\\\"\\u003e\\n \\u003cp\\u003e100 (35/35)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 16px;\\\"\\u003e\\n \\u003cp\\u003e100 (3/3)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 16px;\\\"\\u003e\\n \\u003cp\\u003e100 (32/32)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003c/tr\\u003e\\n \\u003ctr\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 17px;\\\"\\u003e\\n \\u003cp\\u003eOvary\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 16px;\\\"\\u003e\\n \\u003cp\\u003e100 (5/5)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 16px;\\\"\\u003e\\n \\u003cp\\u003e100 (20/20)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 15px;\\\"\\u003e\\n \\u003cp\\u003e100 (25/25)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 16px;\\\"\\u003e\\n \\u003cp\\u003e100 (5/5)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 16px;\\\"\\u003e\\n \\u003cp\\u003e100 (20/20)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003c/tr\\u003e\\n \\u003c/tbody\\u003e\\n\\u003c/table\\u003e\\n\\u003cp\\u003eNote: NA, not applicable.\\u003c/p\\u003e\\n\\u003cp\\u003e\\u003cstrong\\u003eTable 3\\u0026nbsp;\\u003c/strong\\u003eComparison of N-staging results between [\\u003csup\\u003e18\\u003c/sup\\u003eF]-FDG and [\\u003csup\\u003e68\\u003c/sup\\u003eGa]-FAPI-04 using PET/CT and PET/MR\\u003c/p\\u003e\\n \\u003ctable border=\\\"1\\\" cellspacing=\\\"0\\\" cellpadding=\\\"0\\\" width=\\\"126%\\\"\\u003e\\n \\u003ctbody\\u003e\\n \\u003ctr\\u003e\\n \\u003ctd rowspan=\\\"2\\\" valign=\\\"top\\\" style=\\\"width: 3px;\\\"\\u003e\\n \\u003cp\\u003eNO.\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd rowspan=\\\"2\\\" valign=\\\"top\\\" style=\\\"width: 10px;\\\"\\u003e\\n \\u003cp\\u003eLN (Mets/total)\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd rowspan=\\\"2\\\" valign=\\\"top\\\" style=\\\"width: 4px;\\\"\\u003e\\n \\u003cp\\u003epN stage\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd colspan=\\\"6\\\" valign=\\\"top\\\" style=\\\"width: 20px;\\\"\\u003e\\n \\u003cp\\u003e[\\u003csup\\u003e18\\u003c/sup\\u003eF]-FDG PET/CT\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd colspan=\\\"6\\\" valign=\\\"top\\\" style=\\\"width: 20px;\\\"\\u003e\\n \\u003cp\\u003e[\\u003csup\\u003e18\\u003c/sup\\u003eF]-FDG PET/MR\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd colspan=\\\"7\\\" valign=\\\"top\\\" style=\\\"width: 20px;\\\"\\u003e\\n \\u003cp\\u003e[\\u003csup\\u003e68\\u003c/sup\\u003eGa]-FAPI PET/CT\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd colspan=\\\"6\\\" valign=\\\"top\\\" style=\\\"width: 20px;\\\"\\u003e\\n \\u003cp\\u003e[\\u003csup\\u003e68\\u003c/sup\\u003eGa]-FAPI PET/MR\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003c/tr\\u003e\\n \\u003ctr\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 2px;\\\"\\u003e\\n \\u003cp\\u003eTP\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 2px;\\\"\\u003e\\n \\u003cp\\u003eFP\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 3px;\\\"\\u003e\\n \\u003cp\\u003eTN\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 2px;\\\"\\u003e\\n \\u003cp\\u003eFN\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 4px;\\\"\\u003e\\n \\u003cp\\u003eN stage\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 5px;\\\"\\u003e\\n \\u003cp\\u003eEffect\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 2px;\\\"\\u003e\\n \\u003cp\\u003eTP\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 2px;\\\"\\u003e\\n \\u003cp\\u003eFP\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 3px;\\\"\\u003e\\n \\u003cp\\u003eTN\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 2px;\\\"\\u003e\\n \\u003cp\\u003eFN\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 4px;\\\"\\u003e\\n \\u003cp\\u003eN stage\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 5px;\\\"\\u003e\\n \\u003cp\\u003eEffect\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 2px;\\\"\\u003e\\n \\u003cp\\u003eTP\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 2px;\\\"\\u003e\\n \\u003cp\\u003eFP\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 3px;\\\"\\u003e\\n \\u003cp\\u003eTN\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 2px;\\\"\\u003e\\n \\u003cp\\u003eFN\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 4px;\\\"\\u003e\\n \\u003cp\\u003eN stage\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 5px;\\\"\\u003e\\n \\u003cp\\u003eEffect\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd colspan=\\\"2\\\" valign=\\\"top\\\" style=\\\"width: 2px;\\\"\\u003e\\n \\u003cp\\u003eTP\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 2px;\\\"\\u003e\\n \\u003cp\\u003eFP\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 3px;\\\"\\u003e\\n \\u003cp\\u003eTN\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 2px;\\\"\\u003e\\n \\u003cp\\u003eFN\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 4px;\\\"\\u003e\\n \\u003cp\\u003eN stage\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 5px;\\\"\\u003e\\n \\u003cp\\u003eEffect\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003c/tr\\u003e\\n \\u003ctr\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 3px;\\\"\\u003e\\n \\u003cp\\u003e1\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 10px;\\\"\\u003e\\n \\u003cp\\u003e12/28\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 4px;\\\"\\u003e\\n \\u003cp\\u003e3a\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 2px;\\\"\\u003e\\n \\u003cp\\u003e0\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 2px;\\\"\\u003e\\n \\u003cp\\u003e0\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 3px;\\\"\\u003e\\n \\u003cp\\u003e16\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 2px;\\\"\\u003e\\n \\u003cp\\u003e12\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 4px;\\\"\\u003e\\n \\u003cp\\u003e0\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 5px;\\\"\\u003e\\n \\u003cp\\u003e\\u0026darr;\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 2px;\\\"\\u003e\\n \\u003cp\\u003e1\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 2px;\\\"\\u003e\\n \\u003cp\\u003e0\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 3px;\\\"\\u003e\\n \\u003cp\\u003e16\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 2px;\\\"\\u003e\\n \\u003cp\\u003e11\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 4px;\\\"\\u003e\\n \\u003cp\\u003e1\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 5px;\\\"\\u003e\\n \\u003cp\\u003e\\u0026darr;\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 2px;\\\"\\u003e\\n \\u003cp\\u003e3\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 2px;\\\"\\u003e\\n \\u003cp\\u003e0\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 3px;\\\"\\u003e\\n \\u003cp\\u003e16\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 2px;\\\"\\u003e\\n \\u003cp\\u003e9\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 4px;\\\"\\u003e\\n \\u003cp\\u003e2\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 5px;\\\"\\u003e\\n \\u003cp\\u003e\\u0026darr;\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd colspan=\\\"2\\\" valign=\\\"top\\\" style=\\\"width: 2px;\\\"\\u003e\\n \\u003cp\\u003e3\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 2px;\\\"\\u003e\\n \\u003cp\\u003e0\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 3px;\\\"\\u003e\\n \\u003cp\\u003e16\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 2px;\\\"\\u003e\\n \\u003cp\\u003e9\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 4px;\\\"\\u003e\\n \\u003cp\\u003e2\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 5px;\\\"\\u003e\\n \\u003cp\\u003e\\u0026darr;\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003c/tr\\u003e\\n \\u003ctr\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 3px;\\\"\\u003e\\n \\u003cp\\u003e2\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 10px;\\\"\\u003e\\n \\u003cp\\u003e17/57\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 4px;\\\"\\u003e\\n \\u003cp\\u003e3b\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 2px;\\\"\\u003e\\n \\u003cp\\u003e5\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 2px;\\\"\\u003e\\n \\u003cp\\u003e0\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 3px;\\\"\\u003e\\n \\u003cp\\u003e40\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 2px;\\\"\\u003e\\n \\u003cp\\u003e12\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 4px;\\\"\\u003e\\n \\u003cp\\u003e2\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 5px;\\\"\\u003e\\n \\u003cp\\u003e\\u0026darr;\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 2px;\\\"\\u003e\\n \\u003cp\\u003e5\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 2px;\\\"\\u003e\\n \\u003cp\\u003e0\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 3px;\\\"\\u003e\\n \\u003cp\\u003e40\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 2px;\\\"\\u003e\\n \\u003cp\\u003e12\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 4px;\\\"\\u003e\\n \\u003cp\\u003e2\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 5px;\\\"\\u003e\\n \\u003cp\\u003e\\u0026darr;\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 2px;\\\"\\u003e\\n \\u003cp\\u003e5\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 2px;\\\"\\u003e\\n \\u003cp\\u003e0\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 3px;\\\"\\u003e\\n \\u003cp\\u003e40\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 2px;\\\"\\u003e\\n \\u003cp\\u003e12\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 4px;\\\"\\u003e\\n \\u003cp\\u003e2\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 5px;\\\"\\u003e\\n \\u003cp\\u003e\\u0026darr;\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd colspan=\\\"2\\\" valign=\\\"top\\\" style=\\\"width: 2px;\\\"\\u003e\\n \\u003cp\\u003e5\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 2px;\\\"\\u003e\\n \\u003cp\\u003e0\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 3px;\\\"\\u003e\\n \\u003cp\\u003e40\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 2px;\\\"\\u003e\\n \\u003cp\\u003e12\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 4px;\\\"\\u003e\\n \\u003cp\\u003e2\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 5px;\\\"\\u003e\\n \\u003cp\\u003e\\u0026darr;\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003c/tr\\u003e\\n \\u003ctr\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 3px;\\\"\\u003e\\n \\u003cp\\u003e3\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 10px;\\\"\\u003e\\n \\u003cp\\u003e12/28\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 4px;\\\"\\u003e\\n \\u003cp\\u003e3a\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 2px;\\\"\\u003e\\n \\u003cp\\u003e5\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 2px;\\\"\\u003e\\n \\u003cp\\u003e0\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 3px;\\\"\\u003e\\n \\u003cp\\u003e16\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 2px;\\\"\\u003e\\n \\u003cp\\u003e7\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 4px;\\\"\\u003e\\n \\u003cp\\u003e2\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 5px;\\\"\\u003e\\n \\u003cp\\u003e\\u0026darr;\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 2px;\\\"\\u003e\\n \\u003cp\\u003e5\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 2px;\\\"\\u003e\\n \\u003cp\\u003e0\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 3px;\\\"\\u003e\\n \\u003cp\\u003e16\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 2px;\\\"\\u003e\\n \\u003cp\\u003e7\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 4px;\\\"\\u003e\\n \\u003cp\\u003e2\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 5px;\\\"\\u003e\\n \\u003cp\\u003e\\u0026darr;\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 2px;\\\"\\u003e\\n \\u003cp\\u003e5\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 2px;\\\"\\u003e\\n \\u003cp\\u003e0\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 3px;\\\"\\u003e\\n \\u003cp\\u003e16\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 2px;\\\"\\u003e\\n \\u003cp\\u003e7\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 4px;\\\"\\u003e\\n \\u003cp\\u003e2\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 5px;\\\"\\u003e\\n \\u003cp\\u003e\\u0026darr;\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd colspan=\\\"2\\\" valign=\\\"top\\\" style=\\\"width: 2px;\\\"\\u003e\\n \\u003cp\\u003e5\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 2px;\\\"\\u003e\\n \\u003cp\\u003e0\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 3px;\\\"\\u003e\\n \\u003cp\\u003e16\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 2px;\\\"\\u003e\\n \\u003cp\\u003e17\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 4px;\\\"\\u003e\\n \\u003cp\\u003e2\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 5px;\\\"\\u003e\\n \\u003cp\\u003e\\u0026darr;\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003c/tr\\u003e\\n \\u003ctr\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 3px;\\\"\\u003e\\n \\u003cp\\u003e4\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 10px;\\\"\\u003e\\n \\u003cp\\u003e27/49\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 4px;\\\"\\u003e\\n \\u003cp\\u003e3a\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 2px;\\\"\\u003e\\n \\u003cp\\u003e0\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 2px;\\\"\\u003e\\n \\u003cp\\u003e0\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 3px;\\\"\\u003e\\n \\u003cp\\u003e22\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 2px;\\\"\\u003e\\n \\u003cp\\u003e27\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 4px;\\\"\\u003e\\n \\u003cp\\u003e0\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 5px;\\\"\\u003e\\n \\u003cp\\u003e\\u0026darr;\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 2px;\\\"\\u003e\\n \\u003cp\\u003e0\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 2px;\\\"\\u003e\\n \\u003cp\\u003e0\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 3px;\\\"\\u003e\\n \\u003cp\\u003e22\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 2px;\\\"\\u003e\\n \\u003cp\\u003e27\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 4px;\\\"\\u003e\\n \\u003cp\\u003e0\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 5px;\\\"\\u003e\\n \\u003cp\\u003e\\u0026darr;\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 2px;\\\"\\u003e\\n \\u003cp\\u003e0\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 2px;\\\"\\u003e\\n \\u003cp\\u003e0\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 3px;\\\"\\u003e\\n \\u003cp\\u003e22\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 2px;\\\"\\u003e\\n \\u003cp\\u003e27\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 4px;\\\"\\u003e\\n \\u003cp\\u003e0\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 5px;\\\"\\u003e\\n \\u003cp\\u003e\\u0026darr;\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd colspan=\\\"2\\\" valign=\\\"top\\\" style=\\\"width: 2px;\\\"\\u003e\\n \\u003cp\\u003e0\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 2px;\\\"\\u003e\\n \\u003cp\\u003e0\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 3px;\\\"\\u003e\\n \\u003cp\\u003e22\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 2px;\\\"\\u003e\\n \\u003cp\\u003e27\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 4px;\\\"\\u003e\\n \\u003cp\\u003e0\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 5px;\\\"\\u003e\\n \\u003cp\\u003e\\u0026darr;\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003c/tr\\u003e\\n \\u003ctr\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 3px;\\\"\\u003e\\n \\u003cp\\u003e5\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 10px;\\\"\\u003e\\n \\u003cp\\u003e0/32\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 4px;\\\"\\u003e\\n \\u003cp\\u003e0\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 2px;\\\"\\u003e\\n \\u003cp\\u003e0\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 2px;\\\"\\u003e\\n \\u003cp\\u003e2\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 3px;\\\"\\u003e\\n \\u003cp\\u003e30\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 2px;\\\"\\u003e\\n \\u003cp\\u003e0\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 4px;\\\"\\u003e\\n \\u003cp\\u003e1\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 5px;\\\"\\u003e\\n \\u003cp\\u003e\\u0026uarr;\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 2px;\\\"\\u003e\\n \\u003cp\\u003e0\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 2px;\\\"\\u003e\\n \\u003cp\\u003e2\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 3px;\\\"\\u003e\\n \\u003cp\\u003e30\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 2px;\\\"\\u003e\\n \\u003cp\\u003e0\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 4px;\\\"\\u003e\\n \\u003cp\\u003e1\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 5px;\\\"\\u003e\\n \\u003cp\\u003e\\u0026uarr;\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 2px;\\\"\\u003e\\n \\u003cp\\u003e0\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 2px;\\\"\\u003e\\n \\u003cp\\u003e0\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 3px;\\\"\\u003e\\n \\u003cp\\u003e32\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 2px;\\\"\\u003e\\n \\u003cp\\u003e0\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 4px;\\\"\\u003e\\n \\u003cp\\u003e0\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 5px;\\\"\\u003e\\n \\u003cp\\u003e\\u0026rarr;\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd colspan=\\\"2\\\" valign=\\\"top\\\" style=\\\"width: 2px;\\\"\\u003e\\n \\u003cp\\u003e0\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 2px;\\\"\\u003e\\n \\u003cp\\u003e0\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 3px;\\\"\\u003e\\n \\u003cp\\u003e32\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 2px;\\\"\\u003e\\n \\u003cp\\u003e0\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 4px;\\\"\\u003e\\n \\u003cp\\u003e0\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 5px;\\\"\\u003e\\n \\u003cp\\u003e\\u0026rarr;\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003c/tr\\u003e\\n \\u003ctr\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 3px;\\\"\\u003e\\n \\u003cp\\u003e6\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 10px;\\\"\\u003e\\n \\u003cp\\u003e3/30\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 4px;\\\"\\u003e\\n \\u003cp\\u003e2\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 2px;\\\"\\u003e\\n \\u003cp\\u003e3\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 2px;\\\"\\u003e\\n \\u003cp\\u003e0\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 3px;\\\"\\u003e\\n \\u003cp\\u003e27\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 2px;\\\"\\u003e\\n \\u003cp\\u003e0\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 4px;\\\"\\u003e\\n \\u003cp\\u003e2\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 5px;\\\"\\u003e\\n \\u003cp\\u003e\\u0026rarr;\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 2px;\\\"\\u003e\\n \\u003cp\\u003e3\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 2px;\\\"\\u003e\\n \\u003cp\\u003e0\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 3px;\\\"\\u003e\\n \\u003cp\\u003e27\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 2px;\\\"\\u003e\\n \\u003cp\\u003e0\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 4px;\\\"\\u003e\\n \\u003cp\\u003e2\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 5px;\\\"\\u003e\\n \\u003cp\\u003e\\u0026rarr;\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 2px;\\\"\\u003e\\n \\u003cp\\u003e3\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 2px;\\\"\\u003e\\n \\u003cp\\u003e0\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 3px;\\\"\\u003e\\n \\u003cp\\u003e27\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 2px;\\\"\\u003e\\n \\u003cp\\u003e0\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 4px;\\\"\\u003e\\n \\u003cp\\u003e2\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 5px;\\\"\\u003e\\n \\u003cp\\u003e\\u0026rarr;\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd colspan=\\\"2\\\" valign=\\\"top\\\" style=\\\"width: 2px;\\\"\\u003e\\n \\u003cp\\u003e3\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 2px;\\\"\\u003e\\n \\u003cp\\u003e0\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 3px;\\\"\\u003e\\n \\u003cp\\u003e27\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 2px;\\\"\\u003e\\n \\u003cp\\u003e0\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 4px;\\\"\\u003e\\n \\u003cp\\u003e2\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 5px;\\\"\\u003e\\n \\u003cp\\u003e\\u0026rarr;\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003c/tr\\u003e\\n \\u003ctr\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 3px;\\\"\\u003e\\n \\u003cp\\u003e7\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 10px;\\\"\\u003e\\n \\u003cp\\u003e3/56\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 4px;\\\"\\u003e\\n \\u003cp\\u003e2\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 2px;\\\"\\u003e\\n \\u003cp\\u003e0\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 2px;\\\"\\u003e\\n \\u003cp\\u003e0\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 3px;\\\"\\u003e\\n \\u003cp\\u003e53\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 2px;\\\"\\u003e\\n \\u003cp\\u003e3\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 4px;\\\"\\u003e\\n \\u003cp\\u003e0\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 5px;\\\"\\u003e\\n \\u003cp\\u003e\\u0026darr;\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 2px;\\\"\\u003e\\n \\u003cp\\u003e0\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 2px;\\\"\\u003e\\n \\u003cp\\u003e0\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 3px;\\\"\\u003e\\n \\u003cp\\u003e53\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 2px;\\\"\\u003e\\n \\u003cp\\u003e3\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 4px;\\\"\\u003e\\n \\u003cp\\u003e0\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 5px;\\\"\\u003e\\n \\u003cp\\u003e\\u0026darr;\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 2px;\\\"\\u003e\\n \\u003cp\\u003e0\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 2px;\\\"\\u003e\\n \\u003cp\\u003e0\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 3px;\\\"\\u003e\\n \\u003cp\\u003e53\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 2px;\\\"\\u003e\\n \\u003cp\\u003e3\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 4px;\\\"\\u003e\\n \\u003cp\\u003e0\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 5px;\\\"\\u003e\\n \\u003cp\\u003e\\u0026darr;\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd colspan=\\\"2\\\" valign=\\\"top\\\" style=\\\"width: 2px;\\\"\\u003e\\n \\u003cp\\u003e0\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 2px;\\\"\\u003e\\n \\u003cp\\u003e0\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 3px;\\\"\\u003e\\n \\u003cp\\u003e53\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 2px;\\\"\\u003e\\n \\u003cp\\u003e3\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 4px;\\\"\\u003e\\n \\u003cp\\u003e0\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 5px;\\\"\\u003e\\n \\u003cp\\u003e\\u0026darr;\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003c/tr\\u003e\\n \\u003ctr\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 3px;\\\"\\u003e\\n \\u003cp\\u003e8\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 10px;\\\"\\u003e\\n \\u003cp\\u003e0/61\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 4px;\\\"\\u003e\\n \\u003cp\\u003e0\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 2px;\\\"\\u003e\\n \\u003cp\\u003e0\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 2px;\\\"\\u003e\\n \\u003cp\\u003e2\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 3px;\\\"\\u003e\\n \\u003cp\\u003e59\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 2px;\\\"\\u003e\\n \\u003cp\\u003e0\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 4px;\\\"\\u003e\\n \\u003cp\\u003e1\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 5px;\\\"\\u003e\\n \\u003cp\\u003e\\u0026uarr;\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 2px;\\\"\\u003e\\n \\u003cp\\u003e0\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 2px;\\\"\\u003e\\n \\u003cp\\u003e1\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 3px;\\\"\\u003e\\n \\u003cp\\u003e60\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 2px;\\\"\\u003e\\n \\u003cp\\u003e0\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 4px;\\\"\\u003e\\n \\u003cp\\u003e1\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 5px;\\\"\\u003e\\n \\u003cp\\u003e\\u0026uarr;\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 2px;\\\"\\u003e\\n \\u003cp\\u003e0\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 2px;\\\"\\u003e\\n \\u003cp\\u003e0\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 3px;\\\"\\u003e\\n \\u003cp\\u003e61\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 2px;\\\"\\u003e\\n \\u003cp\\u003e0\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 4px;\\\"\\u003e\\n \\u003cp\\u003e0\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 5px;\\\"\\u003e\\n \\u003cp\\u003e\\u0026rarr;\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd colspan=\\\"2\\\" valign=\\\"top\\\" style=\\\"width: 2px;\\\"\\u003e\\n \\u003cp\\u003e0\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 2px;\\\"\\u003e\\n \\u003cp\\u003e0\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 3px;\\\"\\u003e\\n \\u003cp\\u003e61\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 2px;\\\"\\u003e\\n \\u003cp\\u003e0\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 4px;\\\"\\u003e\\n \\u003cp\\u003e0\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 5px;\\\"\\u003e\\n \\u003cp\\u003e\\u0026rarr;\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003c/tr\\u003e\\n \\u003ctr\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 3px;\\\"\\u003e\\n \\u003cp\\u003e9\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 10px;\\\"\\u003e\\n \\u003cp\\u003e0/30\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 4px;\\\"\\u003e\\n \\u003cp\\u003e0\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 2px;\\\"\\u003e\\n \\u003cp\\u003e0\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 2px;\\\"\\u003e\\n \\u003cp\\u003e0\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 3px;\\\"\\u003e\\n \\u003cp\\u003e30\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 2px;\\\"\\u003e\\n \\u003cp\\u003e0\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 4px;\\\"\\u003e\\n \\u003cp\\u003e0\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 5px;\\\"\\u003e\\n \\u003cp\\u003e\\u0026rarr;\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 2px;\\\"\\u003e\\n \\u003cp\\u003e0\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 2px;\\\"\\u003e\\n \\u003cp\\u003e0\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 3px;\\\"\\u003e\\n \\u003cp\\u003e30\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 2px;\\\"\\u003e\\n \\u003cp\\u003e0\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 4px;\\\"\\u003e\\n \\u003cp\\u003e0\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 5px;\\\"\\u003e\\n \\u003cp\\u003e\\u0026rarr;\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 2px;\\\"\\u003e\\n \\u003cp\\u003e0\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 2px;\\\"\\u003e\\n \\u003cp\\u003e0\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 3px;\\\"\\u003e\\n \\u003cp\\u003e30\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 2px;\\\"\\u003e\\n \\u003cp\\u003e0\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 4px;\\\"\\u003e\\n \\u003cp\\u003e0\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 5px;\\\"\\u003e\\n \\u003cp\\u003e\\u0026rarr;\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd colspan=\\\"2\\\" valign=\\\"top\\\" style=\\\"width: 2px;\\\"\\u003e\\n \\u003cp\\u003e0\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 2px;\\\"\\u003e\\n \\u003cp\\u003e0\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 3px;\\\"\\u003e\\n \\u003cp\\u003e30\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 2px;\\\"\\u003e\\n \\u003cp\\u003e0\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 4px;\\\"\\u003e\\n \\u003cp\\u003e0\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 5px;\\\"\\u003e\\n \\u003cp\\u003e\\u0026rarr;\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003c/tr\\u003e\\n \\u003ctr\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 3px;\\\"\\u003e\\n \\u003cp\\u003e10\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 10px;\\\"\\u003e\\n \\u003cp\\u003e0/37\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 4px;\\\"\\u003e\\n \\u003cp\\u003e0\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 2px;\\\"\\u003e\\n \\u003cp\\u003e0\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 2px;\\\"\\u003e\\n \\u003cp\\u003e1\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 3px;\\\"\\u003e\\n \\u003cp\\u003e36\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 2px;\\\"\\u003e\\n \\u003cp\\u003e0\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 4px;\\\"\\u003e\\n \\u003cp\\u003e0\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 5px;\\\"\\u003e\\n \\u003cp\\u003e\\u0026rarr;\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 2px;\\\"\\u003e\\n \\u003cp\\u003e0\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 2px;\\\"\\u003e\\n \\u003cp\\u003e0\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 3px;\\\"\\u003e\\n \\u003cp\\u003e37\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 2px;\\\"\\u003e\\n \\u003cp\\u003e0\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 4px;\\\"\\u003e\\n \\u003cp\\u003e0\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 5px;\\\"\\u003e\\n \\u003cp\\u003e\\u0026rarr;\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 2px;\\\"\\u003e\\n \\u003cp\\u003e0\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 2px;\\\"\\u003e\\n \\u003cp\\u003e0\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 3px;\\\"\\u003e\\n \\u003cp\\u003e37\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 2px;\\\"\\u003e\\n \\u003cp\\u003e0\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 4px;\\\"\\u003e\\n \\u003cp\\u003e0\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 5px;\\\"\\u003e\\n \\u003cp\\u003e\\u0026rarr;\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd colspan=\\\"2\\\" valign=\\\"top\\\" style=\\\"width: 2px;\\\"\\u003e\\n \\u003cp\\u003e0\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 2px;\\\"\\u003e\\n \\u003cp\\u003e0\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 3px;\\\"\\u003e\\n \\u003cp\\u003e37\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 2px;\\\"\\u003e\\n \\u003cp\\u003e0\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 4px;\\\"\\u003e\\n \\u003cp\\u003e0\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 5px;\\\"\\u003e\\n \\u003cp\\u003e\\u0026rarr;\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003c/tr\\u003e\\n \\u003ctr\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 3px;\\\"\\u003e\\n \\u003cp\\u003e11\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 10px;\\\"\\u003e\\n \\u003cp\\u003e1/20\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 4px;\\\"\\u003e\\n \\u003cp\\u003e1\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 2px;\\\"\\u003e\\n \\u003cp\\u003e0\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 2px;\\\"\\u003e\\n \\u003cp\\u003e0\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 3px;\\\"\\u003e\\n \\u003cp\\u003e19\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 2px;\\\"\\u003e\\n \\u003cp\\u003e1\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 4px;\\\"\\u003e\\n \\u003cp\\u003e0\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 5px;\\\"\\u003e\\n \\u003cp\\u003e\\u0026darr;\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 2px;\\\"\\u003e\\n \\u003cp\\u003e0\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 2px;\\\"\\u003e\\n \\u003cp\\u003e0\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 3px;\\\"\\u003e\\n \\u003cp\\u003e19\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 2px;\\\"\\u003e\\n \\u003cp\\u003e1\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 4px;\\\"\\u003e\\n \\u003cp\\u003e0\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 5px;\\\"\\u003e\\n \\u003cp\\u003e\\u0026darr;\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 2px;\\\"\\u003e\\n \\u003cp\\u003e1\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 2px;\\\"\\u003e\\n \\u003cp\\u003e0\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 3px;\\\"\\u003e\\n \\u003cp\\u003e19\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 2px;\\\"\\u003e\\n \\u003cp\\u003e0\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 4px;\\\"\\u003e\\n \\u003cp\\u003e1\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 5px;\\\"\\u003e\\n \\u003cp\\u003e\\u0026rarr;\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd colspan=\\\"2\\\" valign=\\\"top\\\" style=\\\"width: 2px;\\\"\\u003e\\n \\u003cp\\u003e1\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 2px;\\\"\\u003e\\n \\u003cp\\u003e0\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 3px;\\\"\\u003e\\n \\u003cp\\u003e19\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 2px;\\\"\\u003e\\n \\u003cp\\u003e0\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 4px;\\\"\\u003e\\n \\u003cp\\u003e1\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 5px;\\\"\\u003e\\n \\u003cp\\u003e\\u0026rarr;\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003c/tr\\u003e\\n \\u003ctr\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 3px;\\\"\\u003e\\n \\u003cp\\u003e12\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 10px;\\\"\\u003e\\n \\u003cp\\u003e7/40\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 4px;\\\"\\u003e\\n \\u003cp\\u003e3a\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 2px;\\\"\\u003e\\n \\u003cp\\u003e2\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 2px;\\\"\\u003e\\n \\u003cp\\u003e0\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 3px;\\\"\\u003e\\n \\u003cp\\u003e33\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 2px;\\\"\\u003e\\n \\u003cp\\u003e5\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 4px;\\\"\\u003e\\n \\u003cp\\u003e1\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 5px;\\\"\\u003e\\n \\u003cp\\u003e\\u0026darr;\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 2px;\\\"\\u003e\\n \\u003cp\\u003e3\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 2px;\\\"\\u003e\\n \\u003cp\\u003e0\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 3px;\\\"\\u003e\\n \\u003cp\\u003e33\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 2px;\\\"\\u003e\\n \\u003cp\\u003e4\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 4px;\\\"\\u003e\\n \\u003cp\\u003e2\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 5px;\\\"\\u003e\\n \\u003cp\\u003e\\u0026darr;\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 2px;\\\"\\u003e\\n \\u003cp\\u003e4\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 2px;\\\"\\u003e\\n \\u003cp\\u003e0\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 3px;\\\"\\u003e\\n \\u003cp\\u003e33\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 2px;\\\"\\u003e\\n \\u003cp\\u003e3\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 4px;\\\"\\u003e\\n \\u003cp\\u003e2\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 5px;\\\"\\u003e\\n \\u003cp\\u003e\\u0026darr;\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd colspan=\\\"2\\\" valign=\\\"top\\\" style=\\\"width: 2px;\\\"\\u003e\\n \\u003cp\\u003e4\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 2px;\\\"\\u003e\\n \\u003cp\\u003e0\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 3px;\\\"\\u003e\\n \\u003cp\\u003e33\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 2px;\\\"\\u003e\\n \\u003cp\\u003e3\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 4px;\\\"\\u003e\\n \\u003cp\\u003e2\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 5px;\\\"\\u003e\\n \\u003cp\\u003e\\u0026darr;\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003c/tr\\u003e\\n \\u003ctr\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 3px;\\\"\\u003e\\n \\u003cp\\u003e13\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 10px;\\\"\\u003e\\n \\u003cp\\u003e12/27\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 4px;\\\"\\u003e\\n \\u003cp\\u003e3a\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 2px;\\\"\\u003e\\n \\u003cp\\u003e4\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 2px;\\\"\\u003e\\n \\u003cp\\u003e0\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 3px;\\\"\\u003e\\n \\u003cp\\u003e15\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 2px;\\\"\\u003e\\n \\u003cp\\u003e8\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 4px;\\\"\\u003e\\n \\u003cp\\u003e2\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 5px;\\\"\\u003e\\n \\u003cp\\u003e\\u0026darr;\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 2px;\\\"\\u003e\\n \\u003cp\\u003e4\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 2px;\\\"\\u003e\\n \\u003cp\\u003e0\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 3px;\\\"\\u003e\\n \\u003cp\\u003e15\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 2px;\\\"\\u003e\\n \\u003cp\\u003e8\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 4px;\\\"\\u003e\\n \\u003cp\\u003e2\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 5px;\\\"\\u003e\\n \\u003cp\\u003e\\u0026darr;\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 2px;\\\"\\u003e\\n \\u003cp\\u003e4\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 2px;\\\"\\u003e\\n \\u003cp\\u003e0\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 3px;\\\"\\u003e\\n \\u003cp\\u003e15\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 2px;\\\"\\u003e\\n \\u003cp\\u003e8\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 4px;\\\"\\u003e\\n \\u003cp\\u003e2\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 5px;\\\"\\u003e\\n \\u003cp\\u003e\\u0026darr;\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd colspan=\\\"2\\\" valign=\\\"top\\\" style=\\\"width: 2px;\\\"\\u003e\\n \\u003cp\\u003e4\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 2px;\\\"\\u003e\\n \\u003cp\\u003e0\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 3px;\\\"\\u003e\\n \\u003cp\\u003e15\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 2px;\\\"\\u003e\\n \\u003cp\\u003e8\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 4px;\\\"\\u003e\\n \\u003cp\\u003e2\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 5px;\\\"\\u003e\\n \\u003cp\\u003e\\u0026darr;\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003c/tr\\u003e\\n \\u003ctr\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 3px;\\\"\\u003e\\n \\u003cp\\u003e14\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 10px;\\\"\\u003e\\n \\u003cp\\u003e0/35\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 4px;\\\"\\u003e\\n \\u003cp\\u003e0\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 2px;\\\"\\u003e\\n \\u003cp\\u003e0\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 2px;\\\"\\u003e\\n \\u003cp\\u003e0\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 3px;\\\"\\u003e\\n \\u003cp\\u003e35\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 2px;\\\"\\u003e\\n \\u003cp\\u003e0\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 4px;\\\"\\u003e\\n \\u003cp\\u003e0\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 5px;\\\"\\u003e\\n \\u003cp\\u003e\\u0026rarr;\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 2px;\\\"\\u003e\\n \\u003cp\\u003e0\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 2px;\\\"\\u003e\\n \\u003cp\\u003e0\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 3px;\\\"\\u003e\\n \\u003cp\\u003e35\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 2px;\\\"\\u003e\\n \\u003cp\\u003e0\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 4px;\\\"\\u003e\\n \\u003cp\\u003e0\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 5px;\\\"\\u003e\\n \\u003cp\\u003e\\u0026rarr;\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 2px;\\\"\\u003e\\n \\u003cp\\u003e0\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 2px;\\\"\\u003e\\n \\u003cp\\u003e0\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 3px;\\\"\\u003e\\n \\u003cp\\u003e35\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 2px;\\\"\\u003e\\n \\u003cp\\u003e0\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 4px;\\\"\\u003e\\n \\u003cp\\u003e0\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 5px;\\\"\\u003e\\n \\u003cp\\u003e\\u0026rarr;\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd colspan=\\\"2\\\" valign=\\\"top\\\" style=\\\"width: 2px;\\\"\\u003e\\n \\u003cp\\u003e0\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 2px;\\\"\\u003e\\n \\u003cp\\u003e0\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 3px;\\\"\\u003e\\n \\u003cp\\u003e35\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 2px;\\\"\\u003e\\n \\u003cp\\u003e0\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 4px;\\\"\\u003e\\n \\u003cp\\u003e0\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 5px;\\\"\\u003e\\n \\u003cp\\u003e\\u0026rarr;\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003c/tr\\u003e\\n \\u003ctr\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 3px;\\\"\\u003e\\n \\u003cp\\u003e\\u003cstrong\\u003e\\u0026nbsp;\\u003c/strong\\u003e\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 10px;\\\"\\u003e\\n \\u003cp\\u003e\\u003cstrong\\u003e94/530\\u003c/strong\\u003e\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 4px;\\\"\\u003e\\n \\u003cp\\u003e\\u003cstrong\\u003e\\u0026nbsp;\\u003c/strong\\u003e\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 2px;\\\"\\u003e\\n \\u003cp\\u003e\\u003cstrong\\u003e19\\u003c/strong\\u003e\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 2px;\\\"\\u003e\\n \\u003cp\\u003e\\u003cstrong\\u003e5\\u003c/strong\\u003e\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 3px;\\\"\\u003e\\n \\u003cp\\u003e\\u003cstrong\\u003e431\\u003c/strong\\u003e\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 2px;\\\"\\u003e\\n \\u003cp\\u003e\\u003cstrong\\u003e75\\u003c/strong\\u003e\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 4px;\\\"\\u003e\\n \\u003cp\\u003e\\u003cstrong\\u003e\\u0026nbsp;\\u003c/strong\\u003e\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 5px;\\\"\\u003e\\n \\u003cp\\u003e\\u003cstrong\\u003e\\u0026nbsp;\\u003c/strong\\u003e\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 2px;\\\"\\u003e\\n \\u003cp\\u003e\\u003cstrong\\u003e21\\u003c/strong\\u003e\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 2px;\\\"\\u003e\\n \\u003cp\\u003e\\u003cstrong\\u003e3\\u003c/strong\\u003e\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 3px;\\\"\\u003e\\n \\u003cp\\u003e\\u003cstrong\\u003e433\\u003c/strong\\u003e\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 2px;\\\"\\u003e\\n \\u003cp\\u003e\\u003cstrong\\u003e73\\u003c/strong\\u003e\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 4px;\\\"\\u003e\\n \\u003cp\\u003e\\u003cstrong\\u003e\\u0026nbsp;\\u003c/strong\\u003e\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 5px;\\\"\\u003e\\n \\u003cp\\u003e\\u003cstrong\\u003e\\u0026nbsp;\\u003c/strong\\u003e\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 2px;\\\"\\u003e\\n \\u003cp\\u003e\\u003cstrong\\u003e25\\u003c/strong\\u003e\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 2px;\\\"\\u003e\\n \\u003cp\\u003e\\u003cstrong\\u003e0\\u003c/strong\\u003e\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 3px;\\\"\\u003e\\n \\u003cp\\u003e\\u003cstrong\\u003e436\\u003c/strong\\u003e\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 2px;\\\"\\u003e\\n \\u003cp\\u003e\\u003cstrong\\u003e69\\u003c/strong\\u003e\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 4px;\\\"\\u003e\\n \\u003cp\\u003e\\u003cstrong\\u003e\\u0026nbsp;\\u003c/strong\\u003e\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 5px;\\\"\\u003e\\n \\u003cp\\u003e\\u003cstrong\\u003e\\u0026nbsp;\\u003c/strong\\u003e\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd colspan=\\\"2\\\" valign=\\\"top\\\" style=\\\"width: 2px;\\\"\\u003e\\n \\u003cp\\u003e\\u003cstrong\\u003e25\\u003c/strong\\u003e\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 2px;\\\"\\u003e\\n \\u003cp\\u003e\\u003cstrong\\u003e0\\u003c/strong\\u003e\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 3px;\\\"\\u003e\\n \\u003cp\\u003e\\u003cstrong\\u003e436\\u003c/strong\\u003e\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 2px;\\\"\\u003e\\n \\u003cp\\u003e\\u003cstrong\\u003e69\\u003c/strong\\u003e\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 4px;\\\"\\u003e\\n \\u003cp\\u003e\\u003cstrong\\u003e\\u0026nbsp;\\u003c/strong\\u003e\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003ctd valign=\\\"top\\\" style=\\\"width: 5px;\\\"\\u003e\\n \\u003cp\\u003e\\u003cstrong\\u003e\\u0026nbsp;\\u003c/strong\\u003e\\u003c/p\\u003e\\n \\u003c/td\\u003e\\n \\u003c/tr\\u003e\\n \\u003ctr\\u003e\\n \\u003ctd style=\\\"width: 23px;\\\"\\u003e\\u003cbr\\u003e\\u003c/td\\u003e\\n \\u003ctd style=\\\"width: 63px;\\\"\\u003e\\u003cbr\\u003e\\u003c/td\\u003e\\n \\u003ctd style=\\\"width: 27px;\\\"\\u003e\\u003cbr\\u003e\\u003c/td\\u003e\\n \\u003ctd style=\\\"width: 16px;\\\"\\u003e\\u003cbr\\u003e\\u003c/td\\u003e\\n \\u003ctd style=\\\"width: 15px;\\\"\\u003e\\u003cbr\\u003e\\u003c/td\\u003e\\n \\u003ctd style=\\\"width: 20px;\\\"\\u003e\\u003cbr\\u003e\\u003c/td\\u003e\\n \\u003ctd style=\\\"width: 17px;\\\"\\u003e\\u003cbr\\u003e\\u003c/td\\u003e\\n \\u003ctd style=\\\"width: 27px;\\\"\\u003e\\u003cbr\\u003e\\u003c/td\\u003e\\n \\u003ctd style=\\\"width: 32px;\\\"\\u003e\\u003cbr\\u003e\\u003c/td\\u003e\\n \\u003ctd style=\\\"width: 16px;\\\"\\u003e\\u003cbr\\u003e\\u003c/td\\u003e\\n \\u003ctd style=\\\"width: 15px;\\\"\\u003e\\u003cbr\\u003e\\u003c/td\\u003e\\n \\u003ctd style=\\\"width: 20px;\\\"\\u003e\\u003cbr\\u003e\\u003c/td\\u003e\\n \\u003ctd style=\\\"width: 17px;\\\"\\u003e\\u003cbr\\u003e\\u003c/td\\u003e\\n \\u003ctd style=\\\"width: 27px;\\\"\\u003e\\u003cbr\\u003e\\u003c/td\\u003e\\n \\u003ctd style=\\\"width: 32px;\\\"\\u003e\\u003cbr\\u003e\\u003c/td\\u003e\\n \\u003ctd style=\\\"width: 16px;\\\"\\u003e\\u003cbr\\u003e\\u003c/td\\u003e\\n \\u003ctd style=\\\"width: 15px;\\\"\\u003e\\u003cbr\\u003e\\u003c/td\\u003e\\n \\u003ctd style=\\\"width: 20px;\\\"\\u003e\\u003cbr\\u003e\\u003c/td\\u003e\\n \\u003ctd style=\\\"width: 17px;\\\"\\u003e\\u003cbr\\u003e\\u003c/td\\u003e\\n \\u003ctd style=\\\"width: 27px;\\\"\\u003e\\u003cbr\\u003e\\u003c/td\\u003e\\n \\u003ctd style=\\\"width: 32px;\\\"\\u003e\\u003cbr\\u003e\\u003c/td\\u003e\\n \\u003ctd style=\\\"width: 0px;\\\"\\u003e\\u003cbr\\u003e\\u003c/td\\u003e\\n \\u003ctd style=\\\"width: 15px;\\\"\\u003e\\u003cbr\\u003e\\u003c/td\\u003e\\n \\u003ctd style=\\\"width: 15px;\\\"\\u003e\\u003cbr\\u003e\\u003c/td\\u003e\\n \\u003ctd style=\\\"width: 20px;\\\"\\u003e\\u003cbr\\u003e\\u003c/td\\u003e\\n \\u003ctd style=\\\"width: 17px;\\\"\\u003e\\u003cbr\\u003e\\u003c/td\\u003e\\n \\u003ctd style=\\\"width: 27px;\\\"\\u003e\\u003cbr\\u003e\\u003c/td\\u003e\\n \\u003ctd style=\\\"width: 32px;\\\"\\u003e\\u003cbr\\u003e\\u003c/td\\u003e\\n \\u003c/tr\\u003e\\n \\u003c/tbody\\u003e\\n \\u003c/table\\u003e\\n\\u003c/div\\u003e\\n\\u003cp\\u003eAbbreviations: No., number; LN, lymph node(s); Mets, metastases; Total, total number of resected lymph nodes; pN stage, N-staging according to postoperative pathological results; N stage, N-staging according to imaging modality results. Symbols: \\u0026rarr;, unchanged (concordant); \\u0026uarr;, overestimated; \\u0026darr;, underestimated. Definitions: TP, true positive; FP, false positive; TN, true negative; FN, false negative.\\u003c/p\\u003e\"}],\"fulltextSource\":\"\",\"fullText\":\"\",\"funders\":[],\"hasAdminPriorityOnWorkflow\":false,\"hasManuscriptDocX\":true,\"hasOptedInToPreprint\":true,\"hasPassedJournalQc\":\"\",\"hasAnyPriority\":false,\"hideJournal\":false,\"highlight\":\"\",\"institution\":\"\",\"isAcceptedByJournal\":true,\"isAuthorSuppliedPdf\":false,\"isDeskRejected\":\"\",\"isHiddenFromSearch\":false,\"isInQc\":false,\"isInWorkflow\":false,\"isPdf\":false,\"isPdfUpToDate\":true,\"isWithdrawnOrRetracted\":false,\"journal\":{\"display\":true,\"email\":\"info@researchsquare.com\",\"identity\":\"abdominal-radiology\",\"isNatureJournal\":false,\"hasQc\":true,\"allowDirectSubmit\":false,\"externalIdentity\":\"aima\",\"sideBox\":\"Learn more about [Abdominal Radiology](http://link.springer.com/journal/261)\",\"snPcode\":\"261\",\"submissionUrl\":\"https://submission.springernature.com/new-submission/261/3\",\"title\":\"Abdominal Radiology\",\"twitterHandle\":\"\",\"acdcEnabled\":true,\"dfaEnabled\":true,\"editorialSystem\":\"stoa\",\"reportingPortfolio\":\"Springer Hybrid\",\"inReviewEnabled\":true,\"inReviewRevisionsEnabled\":false},\"keywords\":\"Gastric cancer, [68Ga]-FAPI-04, [18F]-FDG, PET/CT, PET/MR\",\"lastPublishedDoi\":\"10.21203/rs.3.rs-8937576/v1\",\"lastPublishedDoiUrl\":\"https://doi.org/10.21203/rs.3.rs-8937576/v1\",\"license\":{\"name\":\"CC BY 4.0\",\"url\":\"https://creativecommons.org/licenses/by/4.0/\"},\"manuscriptAbstract\":\"\\u003cp\\u003e\\u003cstrong\\u003ePurpose\\u003c/strong\\u003e\\u003c/p\\u003e\\n\\u003cp\\u003eThis study aimed to systematically compare the diagnostic performance of gallium-68–labeled fibroblast activation protein inhibitor-04 ([\\u003csup\\u003e68\\u003c/sup\\u003eGa]-FAPI-04) and fluorine-18 fluorodeoxyglucose ([\\u003csup\\u003e18\\u003c/sup\\u003eF]-FDG) for gastric cancer staging using positron emission tomography combined with computed tomography (PET/CT) and positron emission tomography combined with magnetic resonance imaging (PET/MR).\\u003c/p\\u003e\\n\\u003cp\\u003e\\u003cstrong\\u003eMethods\\u003c/strong\\u003e\\u003c/p\\u003e\\n\\u003cp\\u003eIn this single-center retrospective study, 35 patients with pathologically confirmed gastric cancer underwent sequential imaging with [\\u003csup\\u003e68\\u003c/sup\\u003eGa]-FAPI-04 (PET/CT and PET/MR) and [\\u003csup\\u003e18\\u003c/sup\\u003eF]-FDG (PET/CT and/or PET/MR) within 48 hours. Diagnostic performance for primary tumors, lymph node metastases, and distant metastases was evaluated against histopathological results or clinical follow-up. Semi-quantitative parameters, including maximum standardized uptake value (SUV\\u003csub\\u003emax\\u003c/sub\\u003e) and target-to-background ratio (TBR), were compared across tracers and modalities.\\u003c/p\\u003e\\n\\u003cp\\u003e\\u003cstrong\\u003eResults\\u003c/strong\\u003e\\u003c/p\\u003e\\n\\u003cp\\u003e[\\u003csup\\u003e68\\u003c/sup\\u003eGa]-FAPI-04 exhibited significantly higher SUV\\u003csub\\u003emax\\u003c/sub\\u003e and TBR than [\\u003csup\\u003e18\\u003c/sup\\u003eF]-FDG in primary tumors, lymph node and peritoneal metastases. Notably, [\\u003csup\\u003e68\\u003c/sup\\u003eGa]-FAPI-04 maintained consistently high uptake in signet-ring cell carcinoma, a subtype where [\\u003csup\\u003e18\\u003c/sup\\u003eF]-FDG uptake was significantly lower. [\\u003csup\\u003e68\\u003c/sup\\u003eGa]-FAPI-04 PET/MR achieved 100% sensitivity and specificity for peritoneal metastases, significantly outperforming all [\\u003csup\\u003e18\\u003c/sup\\u003eF]-FDG-based modalities. While whole-body PET/CT yielded higher absolute SUV\\u003csub\\u003emax\\u003c/sub\\u003e values, PET/MR demonstrated superior performance in terms of TBR.\\u003c/p\\u003e\\n\\u003cp\\u003e\\u003cstrong\\u003eConclusion\\u003c/strong\\u003e\\u003c/p\\u003e\\n\\u003cp\\u003e[\\u003csup\\u003e68\\u003c/sup\\u003eGa]-FAPI-04 outperforms [\\u003csup\\u003e18\\u003c/sup\\u003eF]-FDG in visualizing primary and metastatic gastric cancer lesions. The combination of [\\u003csup\\u003e68\\u003c/sup\\u003eGa]-FAPI-04 and PET/MR is a particularly effective imaging strategy, delivering superior diagnostic performance for detecting peritoneal metastases and evaluating [\\u003csup\\u003e18\\u003c/sup\\u003eF]-FDG-insensitive subtypes, thereby optimizing precise staging.\\u003c/p\\u003e\",\"manuscriptTitle\":\"[68Ga]-FAPI-04 outperforms [18F]-FDG in gastric cancer staging: a comparative study using PET/CT and PET/MR\",\"msid\":\"\",\"msnumber\":\"\",\"nonDraftVersions\":[{\"code\":1,\"date\":\"2026-02-27 09:11:47\",\"doi\":\"10.21203/rs.3.rs-8937576/v1\",\"editorialEvents\":[{\"type\":\"communityComments\",\"content\":0},{\"type\":\"decision\",\"content\":\"Revision requested\",\"date\":\"2026-03-13T19:47:44+00:00\",\"index\":\"\",\"fulltext\":\"\"},{\"type\":\"editorInvitedReview\",\"content\":\"\",\"date\":\"2026-03-13T18:18:03+00:00\",\"index\":\"hide\",\"fulltext\":\"\"},{\"type\":\"reviewerAgreed\",\"content\":\"13519577866273266159733686467303123574\",\"date\":\"2026-03-04T16:17:48+00:00\",\"index\":\"hide\",\"fulltext\":\"\"},{\"type\":\"editorInvitedReview\",\"content\":\"\",\"date\":\"2026-03-04T12:23:02+00:00\",\"index\":\"hide\",\"fulltext\":\"\"},{\"type\":\"reviewerAgreed\",\"content\":\"331778830236655698067090076867540129797\",\"date\":\"2026-02-24T09:13:50+00:00\",\"index\":\"hide\",\"fulltext\":\"\"},{\"type\":\"reviewersInvited\",\"content\":\"\",\"date\":\"2026-02-23T18:43:38+00:00\",\"index\":\"\",\"fulltext\":\"\"},{\"type\":\"editorAssigned\",\"content\":\"\",\"date\":\"2026-02-23T01:19:02+00:00\",\"index\":\"\",\"fulltext\":\"\"},{\"type\":\"checksComplete\",\"content\":\"\",\"date\":\"2026-02-23T01:17:53+00:00\",\"index\":\"\",\"fulltext\":\"\"},{\"type\":\"submitted\",\"content\":\"Abdominal Radiology\",\"date\":\"2026-02-22T07:22:19+00:00\",\"index\":\"\",\"fulltext\":\"\"}],\"status\":\"published\",\"journal\":{\"display\":true,\"email\":\"info@researchsquare.com\",\"identity\":\"abdominal-radiology\",\"isNatureJournal\":false,\"hasQc\":true,\"allowDirectSubmit\":false,\"externalIdentity\":\"aima\",\"sideBox\":\"Learn more about [Abdominal Radiology](http://link.springer.com/journal/261)\",\"snPcode\":\"261\",\"submissionUrl\":\"https://submission.springernature.com/new-submission/261/3\",\"title\":\"Abdominal Radiology\",\"twitterHandle\":\"\",\"acdcEnabled\":true,\"dfaEnabled\":true,\"editorialSystem\":\"stoa\",\"reportingPortfolio\":\"Springer Hybrid\",\"inReviewEnabled\":true,\"inReviewRevisionsEnabled\":false}}],\"origin\":\"\",\"ownerIdentity\":\"fd117612-e2ca-45f0-ab72-6543aed7f1ba\",\"owner\":[],\"postedDate\":\"February 27th, 2026\",\"published\":true,\"recentEditorialEvents\":[],\"rejectedJournal\":[],\"revision\":\"\",\"amendment\":\"\",\"status\":\"published-in-journal\",\"subjectAreas\":[],\"tags\":[],\"updatedAt\":\"2026-04-27T16:13:04+00:00\",\"versionOfRecord\":{\"articleIdentity\":\"rs-8937576\",\"link\":\"https://doi.org/10.1007/s00261-026-05517-x\",\"journal\":{\"identity\":\"abdominal-radiology\",\"isVorOnly\":false,\"title\":\"Abdominal Radiology\"},\"publishedOn\":\"2026-04-20 15:57:53\",\"publishedOnDateReadable\":\"April 20th, 2026\"},\"versionCreatedAt\":\"2026-02-27 09:11:47\",\"video\":\"\",\"vorDoi\":\"10.1007/s00261-026-05517-x\",\"vorDoiUrl\":\"https://doi.org/10.1007/s00261-026-05517-x\",\"workflowStages\":[]},\"version\":\"v1\",\"identity\":\"rs-8937576\",\"journalConfig\":\"researchsquare\"},\"__N_SSP\":true},\"page\":\"/article/[identity]/[[...version]]\",\"query\":{\"redirect\":\"/article/rs-8937576\",\"identity\":\"rs-8937576\",\"version\":[\"v1\"]},\"buildId\":\"XKTyCvWXoU3ODBz1xrDgd\",\"isFallback\":false,\"isExperimentalCompile\":false,\"dynamicIds\":[84888],\"gssp\":true,\"scriptLoader\":[]}","source_license":"CC-BY-4.0","license_restricted":false}